DAX-1,39 % EUR/USD0,00 % Gold+0,01 % Öl (Brent)+0,32 %

Siga Technology: And the clock goes Tick-Tock - Tick Tock! - 500 Beiträge pro Seite


WKN: 919473 | Symbol: SIGA
6,370
$
23.05.18
Nasdaq
-2,45 %
-0,160 USD

Beitrag schreiben

Begriffe und/oder Benutzer

 

Siga Technology: Patience - but the clock goes tick - tock!

A) Einleitung: Oder was bisher geschah!

Siga Technology verfolge ich schon seit Jahren und bin auch hier investiert. Vorneweg: Ohne daß ich in dieser Zeit das Investment bedauert habe, bei Siga ist Geduld angebracht, da die öffentlichen Mühlen einer Vertragsvergabe für die Bevorratung des Pockenmedikamentes in den USA als Sicherheitsmaßnahmen in Epedemiefällen, langsam mahlen. Seit 2008/2009 aber wird die Story immer konkreter, weil in 2010/2011 Entscheidungen anstehen, die aus dem Forschungsunternehmen mittelfristig ein Mrd. Unternehmen machen können, weil allein ein Medikament von mehreren Medikamenten ST 246, einen Mrd. Markt erschließen wird. Andere Medikamente wie ST 193 oder ST 669 besitzen ähnliches Potential, stehen aber noch nicht vor der Zulassung, wie ST 246 in 2011, besitzen nicht den Fast Track Status, wurden noch nicht mit mehr als 100 Mill. Dollar gefördert bzw. stehen nicht vor der Auftragsvergabe im Mrd. Dollar Bereich von Barda in 2010. Was sind nun die Gründe, weshalb die Company zu einem Mrd.-Unternehmen werden kann in naher Zukunft:


B) Summarise on latest Siga News:

SIGA was at $4 in March and through Sept, kept in the $8 range before a dip to $6 and then a surge to $10 in late Nov. SIGA then it lost 50% of its value, falling to $5 in Dec before establishing a floor at $6 in the last 6 weeks. SIGA has 25+ million shares in the float and over 12% are short-sellers. I believe SIGA is on the Up-Trend and those shorters will begin to ‘buy’ as the stock returns to its high. In its current price range, ACHN is a near-term (3 Mo) ‘Buy on the Dips’ consideration for me. Today, RBC Capital Markets initiated coverage of SIGA with an ‘Outperform’.

SIGA specializes in the development of pharmaceutical agents to fight bio-warfare pathogens and on Jan 19, announced it had staged a full-scale, ‘real’ smallpox bio-attack simulation with the government of Israel. It was the largest bio-defense drill in Israeli history. While no drug was deployed in the maneuvers, hundreds of experts from over 70 countries observed the two-day exercise that took place in and around Tel Aviv.
On Dec 14, SIGA announced the closing of its offering of 2,725,339 shares of common stock to a select group of institutional investors at a price of $7.35 per common share. SIGA plans to use the net proceeds from the sale of the shares for general corporate purposes, including development of the Company's product candidates, the acquisition or in-license of technologies, products or businesses, working capital and capital expenditures.


C)Additional Public Smallpox Stockpile Initiatives in the Pipeline - After Israel now GB want to buy?

Contingency planning for a deliberate release of smallpox in Great Britain - the role of geographical scale and contact structure

Thomas House , Ian Hall , Leon Danon and Matt J Keeling

BMC Infectious Diseases 2010, 10:25doi:10.1186/1471-2334-10-25


Published: 14 February 2010

Abstract (provisional)

Background
In the event of a release of a pathogen such as smallpox, which is human-to-human transmissible and has high associated mortality, a key question is how best to deploy containment and control strategies. Given the general uncertainty surrounding this issue, mathematical modelling has played an important role in informing the likely optimal response, in particular defining the conditions under which mass-vaccination would be appropriate. In this paper, we consider two key questions currently unanswered in the literature: firstly, what is the optimal spatial scale for intervention; and secondly, how sensitive are results to the modelling assumptions made about the pattern of human contacts?

Methods
Here we develop a novel mathematical model for smallpox that incorporates both information on individual contact structure (which is important if the effects of contact tracing are to be captured accurately) and large-scale patterns of movement across a range of spatial scales in Great Britain.

Results
Analysis of this model confirms previous work suggesting that a locally targeted 'ring' vaccination strategy is optimal, and that this conclusion is actually quite robust for different socio-demographic and epidemiological assumptions.

Conclusions
Our method allows for intuitive understanding of the reasons why national mass vaccination is typically predicted to be suboptimal. As such, we present a general framework for fast calculation of expected outcomes during the attempted control of diverse emerging infections; this is particularly important given that parameters would need to be interactively estimated and modelled in any release scenario.


C) Background of RFP Amendment:

Senior Obama Official Steers Sole-Source Contracts to Former Business Associates
by Capitol Confidential
It has been reported, a company by the name of PharmAthene, which is closely tied to the late Congressman John Murtha and Tara O’Toole, an Under Secretary at the Department of Homeland Security (DHS) has received preferential treatment by our good friends in the federal governmenat the expense of Joe Taxpayer.



BIG GOVERNMENT has learned that a little known entity named the Biomedical Advanced Research and Development Authority (BARDA) at the Department of Health and Human Services (HHS) is adding millions of dollars to a contract awarded way back in 2003 that PharmAthene inherited, rather than conducting a fair and open competition. In government speak, that means PharmAthene is about to get huge sums of additional cash without ever having competed for it. Coverage of this sole-source award has already received significant news coverage and attention from numerous outlets, including Citizens for Responsibility and Ethics in Washington (CREW).

But it’s not as if PharmAthene is hiding it. They’re actually promoting the fact that they’re getting sole-source contracts that do away with any competition and fatten their bottom line.

According to a recent PharmAthene press release:


“David P. Wright, President and Chief Executive Officer of PharmAthene, commented, ‘In consultation with BARDA, today PharmAthene submitted a White Paper for advanced development of SparVax(TM) in response to the BAA. If BARDA finds our submission acceptable, a formal proposal will be requested. We believe that, if awarded, funding provided under this BAA, along with potential additional funding under our existing contract with BARDA, will be sufficient to advance SparVax(TM) to a stage where it will be eligible for consideration for a Project BioShield procurement contract.’”

In spite of the fact that Candidate Obama ran and was elected on a pledge to eliminate just these kinds of sole-source contracts, his administration appears to be taking it to a whole new level, particularly when one considers this has do with national security.

The BIG GOVERNMENT question is, why?

BARDA and the Obama Administration (i.e. Tara O’Toole) are propping up PharmAthene all in an effort to position the company to become the national vaccine maker despite having less than 50 employees and a questionable balance sheet .

A little background will be useful here…

Prior to entering the administration, Tara O’Toole ran the Center for Biosecurity at the University of Pittsburgh Medical Center (UPMC) and advised the Alliance for Biosecurity. As has been reported, PharmAthene basically controlled the Alliance and has been working feverishly to get the Center for Biosecurity to become the nation’s government-owned vaccine maker, meaning literally billions for O’Toole’s friends at PharmAthene, who have already enjoyed both earmarks and government contracts at the American people’s expense.

But the timeline here is very interesting. Apparently, the Center for Biosecurity left the Alliance in October of last year, right before O’Toole’s nomination cleared numerous hurdles and she got the job at DHS. Furthermore, in December, with no fanfare whatsoever, PharmAthene got their sole-source contact from BARDA.

http://biggovernment.com/capitolconfiden...


D) Q&A to the Barda smallpox RFP amendment!

Several important inferences from this most recent set of Changes:

First, BARDA continues to actively pursue its objective to acquire a therapeutic smallpox antiviral drug into the Strategic National Stockpile.

Second, we believe SIGA remains uniquely qualified as an offeror for this RFP, with consistent evidence of the excellent therapeutic index of ST-246 in multiple non-human primate tests using the smallpox virus itself and monkeypox.

Third, proof of efficacy in non-human primates remains a substantial barrier to entry that our competitors will need to overcome to commercialize their product candidates. We believe we have at least a three year lead compared to any other potential product candidate in regard to non-human primate efficacy testing.

Will the changes in the RFP delay a contract for the RFP?

The original RFP solicitation stated the intent to come to contract by September 2009, while BARDA officials have previously stated their expectation to complete a contract by the end of calendar year 2009. We believe it is unlikely we will consummate a contract in this calendar year, but we have been engaged with BARDA contracting personnel in an active, diligent process regarding technical aspects of our proposal, physical and informational security at our laboratories and our manufacturing contractors’ plants, and pricing. We don’t believe that Friday’s amendments to the RFP will adversely affect our prospects in this process.

Also, we don’t believe the December 11th amendment will create a long process delay, so we continue to await the finalization of the amendment on or about December 28. We find this process to be entirely consistent with the contracting processes we have engaged in with HHS and DOD for our prior grants and contracts. We have the highest respect for the diligence and integrity of the process and our government partners.

If BARDA makes awards to multiple contractors, will that diminish SIGA’s share of the base acquisition of 1.7 million courses of drug?

While this is certainly possible, we believe we are best able to deliver the entire 1.7 million courses as rapidly as possible.

Our pricing proposal only contemplated an order for the entire 1.7 million courses. We believe that BARDA has shown an understanding both in this RFP and its acquisitions that lower volumes deserve higher unit pricing.



Will these delays postpone potential delivery of ST-246 into the strategic national stockpile?


We have already produced 20,000 courses of ST-246 in our FDA registration batches and plan to produce 300,000 more courses in early 2010 in our commercial validation process. This activity is funded by the $20 million increase to our ST-246 therapeutic development contract which BARDA awarded to us in September 2008.
We believe that if we complete a contract in the first quarter of 2010, we can fulfill our plan to begin delivery of our drug into the strategic national stockpile in late 2010.




E) Conclusion: After contract award price target 11 - 26 Dollar!

SIGA Technologies (SIGA): Initiate coverage w/ Outperform; to be awarded a big gov. contract - RBC Capital

January 28, 2010 8:43 AM EST


From Notable Calls

RBC Capital is picking up coverage on SIGA Technologies ( NASDAQ : SIGA) with Outperform rating and $11 price target, while noting that depending on contract size SIGA's NPV could be as high as $26/per share.

Firm notes their positive thesis is based on the likelihood that SIGA Technologies, Inc. will be awarded a lucrative contract under Project BioShield to supply the U.S. Government with its oral treatment for smallpox (ST-246, tecovirimat). SIGA shares traded lower following an unexpected amendment to the Request for Proposals (RFP), which they believe creates an attractive entry point. The timing of a contract is uncertain but is likely to occur in the firsthalf 2010. The recent negative assessment of the U.S. Government’s preparedness also increases political pressure to get a contract signed, in RBC's opinion. The simple oral dosing, compelling animal data, anecdotal efficacy in humans against related viral infections, and secure and audited supply chain make ST-246 an attractive asset to the U.S. Government and others interested in effective counter measures against smallpox.


Key Reasons to Expect BARDA Contract

- Small pox counter measures are a high priority at Biomedical Advanced Research and Development Authority (BARDA) given the vulnerability of the population following the discontinuation of routine vaccination in 1972.

- Only two known drugs are vying for the government contract, and the amended RFP permits the government to acquire both.

- ST-246 has demonstrated safety in humans and efficacy across multiple animal species, including non-human primates.

- This week a bipartisan commission issued a scathing report giving the U.S. Government an “F” for preparedness, increasing the political pressure for the government to act now.


Initial Contract worth Approximately $500 million; Expansion Potential to over $1 billion

- Assuming $250-300 per course of treatment and an initial contract for 1.7 million courses, the total sale could be $425-510 million over a three-year period.

- The initial contract has an option to expand to 12 million courses (a blockbuster opportunity even if price is adjusted downward for the increased volume).

- Other governments are likely to place orders after the United States

Competition – Room for Two Drugs
- Privately held Chimerix Inc. is developing a competitive agent for the treatment of smallpox. Because Chimerix is private, there are limited public disclosures regarding the status of its program.

- CMX001 is Chimerix’s oral version of the broadly active antiviral cidofovir. It is active in most animal models of smallpox but cannot be tested in non-human primates, which may provide a competitive advantage for SIGA because the RFP requires that the company demonstrates efficacy in non-human primates.

Governmental Purchasing and Regulation are the Key Risks
SIGA is seeking government contracts for ST-246. As a result, SIGA is dependent on the vagaries of timing, purchase size and pricing. The U.S. Government could also change its mind or amend the contract. In addition, gaining FDA approval will require SIGA to use the ‘animal rule’ because efficacy studies in humans are not possible with smallpox. Although there are guidelines for approval based on animal studies, the path is not well trodden, and there remains significant regulatory risk. FDA approval is not necessary for initial government purchases, but it may be required for longer-term contracts or sales in other countries.

Government Funding History Suggests Strong Interest in ST-246
Over the past-two years, SIGA has received contracts and grants totalling $78 million specifically for the development of ST-246. This amount includes a $55 million contract to develop alternative intravenous formulations of ST-246 for seriously ill patients and a $20 million extension to a $16.5 million, 2006, three-year contract for the development of ST-246. Given the government’s investment in this program, and the advanced stage of clinical and regulatory development of the program, we believe a contract to purchase ST-246 for the Strategic National Stockpile (SNS) is highly likely.

Notablecalls: SIGA Tech (SIGA) certainly presents an interesting situation for traders here as RBC Capital seems to be the 1st firm to pick up coverage on this biodefense name. Biodefense (and homeland def. in general) has become a hit topic once again & contracts usually follow.

Note that SIGA has a long history getting funding from the U.S. Government. Since 2004, SIGA has secured approximately $122 million in government grants, contracts and awards to fund the development of ST-246 and other novel antiviral agents.

I really don't think the Government will leave SIGA empty-handed after plowing $100m+ into the co.

As noted, RBC estimates the stock could be worth up to $26 if everything goes right. That's some upside.

I think this call will get traders' attention and will serve to push the stock higher by 10%+, putting $7 level possibly in plays.

F) And the clock goes tick-tock tick-tock!

Just a reminder for those who are thinking ONLY of this therapeutic smallpox RFP that SIGA is bidding on now.....there should be additional US purchases to follow.

While the international market is huge, there are probably prophylaxis, geriatric/IV, and adolescent/suspension formulations of 246 still to come in new RFPs from the US Government. While the geriatric/IV formula might be small...but expensive potatoes, a new prophylaxis RFP could easily be as big, if not bigger than, the therapeutic... RFP... particularly if the dosage is different. Dr. Rose has mentioned on several occasions that 25% of the US population base is under 10 years old or younger so there is an appreciable market there with another RFP too.

One of the initial RFP questions asked if the 12M additional courses included any of the other types of courses....the answer was may or may not on prophylaxis....but there would be additional contracts to address other formulations. (question 21)

IMO, this definitely means some portion of the 12M additional courses should be bought at a minimum. Lots more growth over the the next couple of years in the basic contract to fund further pipeline development.


Antwort auf Beitrag Nr.: 38.978.765 von Kleiner Chef am 20.02.10 12:00:23Hallo Kleiner Chef,

super, dass du diesen Thread aufgemacht hast und danke für die Infos.
Hoffe, dass unsere Erwartungen sich erfüllen.
Antwort auf Beitrag Nr.: 38.988.240 von _pilot am 22.02.10 19:29:24Aber gerne. Ich denke Siga hat die Aufmerksamkeit auch in DE verdient, denn die Perspektiven sind voll in intakt, wenngleich es in den letzten Tagen eher ruhig war. Das kann sich aber sehr schnell ändern:yawn:
Antwort auf Beitrag Nr.: 38.988.570 von Kleiner Chef am 22.02.10 20:05:52ja ja die geduld
wer bring die schon mit
wenn nicht 2 forsysindianer
viel glück uns allen

@pilot
treffen in deiner nähe wahrscheinlich in steinfurt
Antwort auf Beitrag Nr.: 39.005.046 von Bachalor am 24.02.10 18:56:23Bei Siga tut sich was!
Siga präsentiert sich auf der Investorenkonferenz von RBC und Cohen. RBC hat im Update übrigens von einer Auftragserteilung innerhalb der nächsten 2 Monate gesprochen.

Bei Inside Wall Street sieht man Siga bei 12 Dollar!

Inside Wall Street: Comeback Time for Bio-Defense Stocks?
By GENE MARCIAL


Remember those bio-defense stocks that Wall Street totally embraced after the Sept. 11 terrorist attacks? When Congress passed the Project BioShield Act of 2004, it encouraged a raft of companies to engage in developing bio-medical countermeasures to protect Americans from so-called bio-terrorists. Companies in this group attracted investors with their potential to combat attacks that use chemicals, anthrax, smallpox or even nuclear radiation as weapons.

Well, investor interest in bio-defense companies ultimately flamed out as government funding for their projects wasn't adequate. And eventually fear gave way to complacency, and to most people bio-terrorism has come to seem like a thing of the past.

Now, though, some analysts and investors believe the bio-defense group will stage a comeback because they expect government financing for these projects will start gaining more attention under the Obama administration. In his State of the Union address, the president unveiled a plan for a quicker response to bioterrorism threats and attacks. He asked government leaders to rethink their plans for medical countermeasures so that quick, reliable and affordable antidotes will be available during any public health emergency.

"It seems like the government will finally step up to the plate and show real concern and support," says one investment manager who has started accumulating shares of some bio-defense plays.

Regaining Traction

Jason Kolbert, analyst at National Securities who tracks bio-defense companies, says shares of the group's leaders have been under downward pressure. PharmAtene (PIP), which is developing biological and chemical defense products, has slumped to a low of $1.13 a share on Dec. 11, 2009, from a 52-week high of $4.31 on Sept. 10, 2009. It has edged up since to just $1.97.

But Kolbert is optimistic that shares of selected bio-defense stocks will start gaining traction as government agencies, such as the Department of Defense and National Institutes of Health, step up the awarding of contracts to purchase anti-terrorism biological products. And the government has been stockpiling large quantities of medicine and medical supplies to meet any public health emergency. The medicines are expected to be delivered to any state in the U.S. within 12 hours after an attack or emergency situation.

Here are three stocks that some analysts believe have the best chances of participating in the next bio-defense upswing:

•Siga (SIGA), whose chief product, ST-246, is an orally administered small-molecule antiviral that targets smallpox.


•Aeolus Pharmaceuticals (AOLS), which is developing products against biological, chemical and radiological weapons.
•Soligenix (SNGX), whose bio-engineered vaccine is designed to protect against the effects of ricin toxin, a lethal biological agent.

Siga is close to achieving its first commercial success, says Kolbert, predicated on getting a purchase contract from the Biomedical Advanced Research and Development Authority (part of the Health and Human Services Department) for its ST-246 smallpox vaccine. Since 2003, Siga has received about $35.8 million from the National Institute of Allergy and Infectious Diseases (NIAID) to help develop the product.

Siga's stock, which hit a 52-week high of $10 a share on Nov. 30, 2009, has tumbled to $6.47. Kolbert figures it's worth $12, based on projected cash flows for its ST-246 smallpox vaccine.
[/u]

Aeolus, whose stock has rallied to a 52-week high of 55 cents a share on Oct. 22, 2009, from 15 cents on Mar. 2, 2009, is way undervalued, figures Kolbert. Aeolus is developing AEOL 10150, a medical countermeasure against the effects of acute radiation syndrome and mustard and chlorine gas in the lungs.

Soligenix's microcap stock has been on the go, leaping from 10 cents on Apr. 24, 2009 to 37 cents on Sept. 21, 2009. Chrystyna Bedrij, analyst at Griffin Securities, rates the stock a buy with a 12-month price target of $1.40. "Soligenix is the world leader in ricin toxin research, and its vaccine, Rivax, has shown to be well tolerated and immunogenic in a Phase 1 clinical trials in normal volunteers," says Bedrij.

Ricin and the bacterial agent anthrax are emerging as the most prevalent agents against which the U.S. is trying to develop bio-defenses, says Bedrij. Soligenix has been granted $9.4 million by the NIAID to help develop the product.

Big Bets by Some Big Names

These bio-defense stocks are hardly household names, but some large institutional investors are beginning to nibble. BlackRock Institutional Investors and BlackRock Fund Advisers have accumulated a combined stake of about 4% of Siga's stock. The biggest Siga stakeholder is Ronald Perelman, who owns 14%.

At Aeolus, XMark Opportunity Partners has built up a 53% stake, and Efficacy Entities owns 20%.

At Soligenix, Sigma Tau Finanziari is the biggest stakeholder, with 24.5% of the stock, and Biotex Pharma Investors owns 9.5%.

While Siga, Aeolus, and Soligenix are little known microcap stocks, and duly depressed (in price) at that, the big bets by large investors do lend some credibility to an otherwise overlooked group.


Antwort auf Beitrag Nr.: 39.044.418 von Kleiner Chef am 02.03.10 19:53:14danke für die Info
RBC Investor Präsentation - Biodefense Panel Discussion


Folgende Companies standen Rede und Antwort:

BioCryst Pharmaceuticals, Inc (BCRX)
Emergent Biosolutions (EBS)
SIGA Technologies, Inc. (SIGA)

Hier der Link über die Diskussion:

http://investor.siga.com/events.cfm


Folgende wesentliche Aussagen der Diskussion:

1) Obviously the contract being awarded in "weeks or months, not years"
2) The comment she made that said yes, SIGA does know where they are in the process. (paraphrasing) There are known steps to take in this process and the only unknown is when the next step will come. But they know when they get to the last steps. And also, when the number of questions narrows in each step, they know they are close as well.
3) Mock trial in Israel was good for 2 reasons...to choose smallpox emphasized that goverments see smallpox as a real threat and to choose SIGA re-emphasized the fact that SIGA is the only one with a solution for smallpox
4) International market comment (good & bad): some countries require FDA approval, some don't (Israel and Canada don't)...FDA approval would definitely open up the market.
5) "Limited players in this space...with this core competency. (bio terrorism focus) You see the same companies over and over. And once you are in this market you are likely to succeed".
6) Like the comment by one of the other guys that commented on thier pricing negotiations with BARDA. "Pleasantly suprised with pricing negotiations with BARDA. Fair and balanced discussion."


Nächste Woche geht es weiter am 10.03 auf der Cohen Investor-Konferenz und am 11.03. gibt die Jahreszahlen 2009.
Antwort auf Beitrag Nr.: 39.078.713 von Kleiner Chef am 07.03.10 13:57:41Kl. Chef,

geht´s weiter? 7,15 - wegen der Cohen Investor-Konferenz

oder schon im Hinblick auf die Zahlen?

Wird mal Zeit, dass Bewegung reinkommt ...
Antwort auf Beitrag Nr.: 39.106.539 von _pilot am 10.03.10 17:43:46Wie´s weitergeht? Wenn man das wüßte. Die Zahlen sind noch nicht out. Meistens waren die Kursreaktionen auf die Zahlen nicht positiv. Andererseits gibt es heute ein Update auf den Status im Prozess um das FDA-Approval von ST-246. Schaun wir mal.


Gruß
tick-tock, tick-tock ...

geht was heute?

Chef, wann kommen die Zahlen?
Antwort auf Beitrag Nr.: 39.115.957 von _pilot am 11.03.10 17:13:52Die Zahlen sind da, aber eher ein Non-Event. Die CC ist sicherlich interessanter, da hier auch die nähere Zukunft beleuchtet wird:

a) 2009er Zahlen

SIGA Technologies Reports Financial Results for the Fourth Quarter and Full Year of 2009

Buzz up! 0 Print..Companies:SIGA Technologies, Inc..Related Quotes
Symbol Price Change
SIGA 7.36 +0.23


{"s" : "siga","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: SIGA Technologies, Inc. On Wednesday March 10, 2010, 4:05 pm EST

NEW YORK, March 10, 2010 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced its financial results for the year ended December 31, 2009.



For the full year 2009, total revenues were $13.8 million as compared to $8.1 million in 2008, and net operating loss was $11.9 million as compared to $8.7 million in 2008. Net loss per common share was $0.47 as compared to $0.25 in 2008. SIGA's performance in 2009 was mainly driven by the continued development of ST-246(R), including completion of a Phase II human safety clinical trial and the initiation of the commercial manufacturing validation campaign.



For the fourth quarter of 2009, total revenues were $4.0 million as compared to $2.5 million in 2008, and operating loss was $3.7 million as compared to $2.5 million in 2008.



Total assets as of December 31, 2009 were $25.9 million as compared to $8.8 million on December 31, 2008.



Ayelet Dugary, Chief Financial Officer of SIGA Technologies, stated, "We ended the year with a stronger balance sheet, greater liquidity and significant institutional investor support. During 2009, we raised approximately $20 million, which has positioned us to meet our commitments and invest in our programs."



2009 Key Financial Results



Revenues



For 2009, revenues from research and development contracts and grants were $13.8 million, an increase of $5.7 million, or 71.2%, from $8.1 million in 2008. This increase is due mainly to an increase in revenues recognized from our existing program to establish large-scale manufacturing and packaging of ST-246 and revenue recognized from our contract for additional formulations and indications of ST-246.



Research and Development



For 2009, research and development expenses were $17.4 million, an increase of $5.8 million, or 50%, from $11.6 million in 2008. Expenditures related to the manufacturing, packaging, and stability testing of ST-246 increased $3.3 million. Other costs related to ST-246 and the development of our other lead drug candidates increased $1.2 million from the prior year. Employee compensation expenses increased $978,000, mainly due to the hiring of additional expert R&D and support personnel.



Selling, General and Administrative Expenses



For 2009, selling, general and administrative expenses were $7.5 million, an increase of $2.9 million, or 64%, from $4.6 million in 2008. This increase is due mainly to higher stock-based compensation charges, higher general corporate and litigation legal support, and an increase in accounting fees.



Financial Condition and Liquidity



Cash, cash equivalents and short-term investments at December 31, 2009 were $14.5 million and $5.0 million, respectively, as compared to a cash and cash equivalents balance of $2.3 million at December 31, 2008. In 2009, we strengthened our balance sheet with the sale of 2.7 million shares of our common stock for net proceeds after offering expenses of $18.6 million, in addition to receipt of $7.4 million of proceeds from exercises of warrants and options to acquire shares of our common stock.



Annual Report on Form 10-K



SIGA is filing today with the Securities and Exchange Commission its Annual Report on Form 10-K for its fiscal year ending December 31, 2009. SIGA urges its investors to read this Annual Report on Form 10-K for further details concerning the Company. The Annual Report on Form 10-K is also available on the Company's website, at http://www.siga.com.


b) Zusammenfassung Conference Call:

GREAT CONF CALL! 10-Mar-10 11:14 pm Ok...so to recap...even the most skeptical of LONGS have said the call today was MUCH more informative and positive then previous calls. Here's my high level take...

- Definitive positive statement about a security/technical update to BARDA with an expected response in 3 weeks and THAT event being the "ULTIMATE STEP" (to a contract?)
- Very positive statement about subsequent foreign orders
- Very positive statements about the POTENTIAL and PROGRESS of the rest of SIGA's pipeline
- Very positive assessment about the financial stability of the company



c: Fazit:
Mit 50 % Kurssteigerung seit Jahresanfang ist die Entwicklung gut. Die Spannung wächst mit jeder Woche, da die Auftragsvergabe immer näher rückt, was auch der Grund sein sollte, das die 2009er Zahlen nicht als Non-Event bzw. Sell on good news gesehen werden. Grundsätzlich kann man sich über Siga immmer auf dem Laufenden halten, wenn man sich hier einen Überblick verschafft:


http://messages.finance.yahoo.com/mb/SIGA


Servus Miteinander,

inwiefern können noch Probleme mit PharmAthene auftreten, folgende News kam gestern über die Ticker:

http://www.prnewswire.com/news-releases/pharmathene-reports-…

Ein kurzer Auszug daraus:

Mr. Wright continued, "Regarding the Company's ongoing litigation with SIGA Technologies, discovery in the case was completed in February. On March 19th SIGA filed a motion for summary judgment. PharmAthene's reply brief and any cross motions for summary judgment are due in April, and we believe we have several persuasive counter-arguments. All other summary judgment related briefs are due from both parties in May. We anticipate the court will hold a hearing on the motions in June or July. Thereafter, once the court rules on the motions for summary judgment, and assuming no open issues remain in the case, the parties can then ask the court to set a trial date. We continue to believe that our case has merit and intend to pursue it vigorously."

Kennt jemand noch genauere Hintergründe, warum der Merger damals gecancelt wurde?

cultom
FDA approves smallpox vaccine's delivery
by Ted Purlain on March 22, 2010

Bavarian Nordic, a Danish biotechnology company, has announced that the FDA has decided that all requirements for delivery of the company's smallpox vaccine to the United States government have been met.

The FDA's announcement means that Bavarian Nordic will deliver 20 million doses of Imvamune to the U.S., which will fulfill a contract currently being held.

"What remains are some administrative procedures that need to get in place," Chief Executive Officer Anders Hedegaard told Reuters. "Our firm expectation is that we will start deliveries on this order in the first half of 2010."

Delivery on the contract was originally set to begin by the end of 2009 but was delayed while the Bavarian company made the required adjustments to its facilities. The FDA has now accepted the company's actions to address the observations.

"This was the last step along with the clinical and preclinical data that will be used to potentially support the use of Imvamune following a declared emergency," Bavarian told Reuters. "Subsequently, the company will scale-up the production as planned ... so the 20 million doses will be produced and delivered according to the contract."

Bavarian has said that it will deliver as many as five million doses of Imvamune to the U.S. this year.

http://www.bioprepwatch.com/news/212536-fda-approves-smallpox-vaccines-delivery
Antwort auf Beitrag Nr.: 39.207.917 von cultom4president am 24.03.10 17:42:17@cultum
Wenn man nach der Verlautbarung geht von Siga, so war wohl die öffentlichen Mittel der Hauptgrund, die sich mittlerweile auf über 100 Mill. Dollar belaufen, somit Siga die Entwicklung von ST-246 selbstständig aus eigenen Mitteln betreiben kann:

SIGA Terminates Merger Agreement with PharmAthene, Inc.
News source: Business Wire

SIGA Technologies, Inc. (NASDAQ: SIGA) disclosed today that it had terminated its Agreement and Plan of Merger with PharmAthene, Inc., pursuant to the terms of that agreement.

In reaching its decision, the SIGA Board of Directors considered many factors, including recent positive scientific data and the receipt of approximately $27 million in grants for its smallpox and arenavirus programs over the last several months, which amount includes a grant of $16.5 million from the National Institutes of Health also announced today.

Donald Drapkin, Chairman of the Board of SIGA, commented, "SIGA is excited about its future and committed to the development and successful completion of its lead product candidate, SIGA-246, a smallpox antiviral treatment, as well as its other anti-viral and anti-infective programs."

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA has the potential to become a significant force in the discovery of vaccine and pharmaceutical agents to fight emerging pathogens. SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria. In addition to smallpox, SIGA has antiviral programs targeting other Category A viral pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).
Antwort auf Beitrag Nr.: 39.209.270 von Kleiner Chef am 24.03.10 20:38:28Vielen Dank für die schnelle Info,

bin gespannt ob daraus noch größere Rechtsstreitigkeiten resultieren werden.

cultom
Analyst Raises SIGA Estimates to $11 per Share

SIGA Technologies, Inc. (SIGA, Free Analysis), a drug development company in the biodefense industry, has moved significantly off of its $4.73 52-week lows, but remains undervalued according to at least one analyst. Noble Financial raised its price target from $7 to $11 per share, and maintained its Buy rating on the company.

Earlier this month, RBC also released positive comments on the company after a conference panel. The analyst saw significant near-term potential upside in the stock due to an expected contract with the U.S. Government and maintained its own Outperform rating on the stock. On April 1st, the company is also meeting with RBC Capital in Boston.
Antwort auf Beitrag Nr.: 39.324.579 von _pilot am 13.04.10 15:54:40_pilot

das es noch was wird :p

wann es was wird :mad:

wenn es was wird :D
Siga scheint wieder etwas zu drehen, gestern schön positiv und heute vorbörslich nochmal etwas hoch. Mal schauen ob wir heute die 7USD wieder knacken und uns dann wieder in Richtung alter Höchststände aufmachen.

Durchaus spannend hier! ;)

cultom
Antwort auf Beitrag Nr.: 39.368.740 von Bachalor am 20.04.10 16:54:21In der Tat wird die Investorengemeinde ungeduldig!

Investorengemeinde? Nein besser die Daytrader! Denen
dauert die Entwicklung zu lange. Solange das Volumen
so hoch ist, wie aktuell, wird es mit 7 Dollar in der
Tat zäh!

Die Investoren schauen sich die Entwicklung von der Seite
an. Solange es immer wieder Studien gibt, die für 2011
ein EPS von 1,75 - 2 Dollar vorhersagen, wie jetzt wieder
geschehen, bestätigt dies die Erwartungshaltung der
Investoren:p
Antwort auf Beitrag Nr.: 39.381.402 von Kleiner Chef am 22.04.10 10:35:54Keine Sorge,

die 7USD werden schon noch fallen! ;)
Man will ja investieren und nicht spekulieren.

cultom
Antwort auf Beitrag Nr.: 39.386.690 von Bachalor am 22.04.10 20:30:58Schön auf Tageshoch geschlossen und die 7USD überwunden. Was will man mehr!!

cultom
Vorbörslich geht es schon auf 7,25USD. Bin mal gespannt wann die ersten News durchsickern. Immerhin sollte in diesem Quartal noch einiges anstehen.
Antwort auf Beitrag Nr.: 39.386.690 von Bachalor am 22.04.10 20:30:58@bachelor: Kannst ruhig öfters meckern zu dem Kursverlauf. Vielleicht wird es dann wieder was mit einem erneuten Kurssprung:kiss:
Antwort auf Beitrag Nr.: 39.392.430 von Kleiner Chef am 23.04.10 16:08:40ist größere hürde

qcultom
vörbörslich ja top
aber dann


na,der tagist noch lange

ps:
dein traderbörsenspiel auf ariva sieht wie fast jedes jahr tiop aus
entwickelt sich prima
und das ohne zu traden:cool:
apple sei dank:cool:
Antwort auf Beitrag Nr.: 39.393.469 von Bachalor am 23.04.10 18:10:13man
meine dicken finger:mad:
ihr versteht den sinn
trotz einiger falscher und zu vieler buchstaben
Antwort auf Beitrag Nr.: 39.393.469 von Bachalor am 23.04.10 18:10:13Naja, die 7USD wollten nicht halten, aber nächste Woche geht es ja weiter.

@Bachalor

Ja Apple macht mir seit 2006 sehr große Freude. Aber das diskutieren wir in einem anderen Forum.

Allen ein schönes Wochenende!

cultom
mmmmhhhhhh:rolleyes:
die 7 sind zäh
man lugt mal vorbörslich oder während dem handel drüber
aber ist schwierig

mal so sk 7,20-7.25 wäre mal jut


also weiter watten und geduld

Antwort auf Beitrag Nr.: 39.495.446 von _pilot am 10.05.10 21:31:28Charttechnisch sind wir wieder auf einem guten Weg, vorallem da auf TH geschlossen wurde. Für die nächsten Wochen erwarte ich gute NEWS seitens von SIGA.

Seit langem mal wieder ein interessanter Biotech-Wert. ;)

cultom
Antwort auf Beitrag Nr.: 39.496.688 von cultom4president am 11.05.10 07:53:14
Q1 Zahlen und Kursentwicklung

Hatte noch keine Gelegenheit den CC zu hören, aber Fragen zum Status der Auftragsvergabe von Barda waren untersagt, d.h. entweder

a) man hat einen Maulkorp verpasst bekommen von höherer Stelle oder
b) Verhandlungsstadium ist soweit fortgeschritten, das eine "Quiet period" läuft,

letzteres könnte auch von anderen Investoren so interpretiert werden. Die Q1 Zahlen waren somit vor diesem Hintergrund ein Non-Event.

PS: Jetzt noch anziehendes Volumen bei Siga und es wird spannend.

Gruß
war am ende nochmal schmackes bei volumen und kurs


gespannt bin

Antwort auf Beitrag Nr.: 39.499.530 von Bachalor am 11.05.10 14:14:40@
bruchpilot
;)



7,51$
Antwort auf Beitrag Nr.: 39.502.053 von Bachalor am 11.05.10 18:55:36
Bacha, bis jetzt habe ich die Flieger immer noch heil gelassen.

:D

Hoffentlich kommt mal ein bisschen Action hier rein -
ist ja langweiliger als Fliegen.
Antwort auf Beitrag Nr.: 39.510.203 von _pilot am 12.05.10 19:18:44bald rollst du da drüber




die baustelle ist top
war mal nachts da,habe es mir angesehen:cool:


wie im baukastensystem
leider werden die brücken dann so eingebaut
dass man uberfahrende A380 usw nicht sehen kann

sonst passieren zu viele unfälle vor schaulustigen:laugh:

die A3 ffm-köln
ist sowoeso die autobahn mit den meisten schweren unfällen in deutschland,
da viele meinen sie müssten wettrennen mit dem parallel verlaufenden ICE fahren:(


siga hat wohl die 7 endgültig genommen:cool:
Die 8USD wurden schonmal getestet.
Ich denke es geht so langsam in Richtung Jahreshoch!

cultom
Antwort auf Beitrag Nr.: 39.539.965 von cultom4president am 18.05.10 16:16:16Meinte natürlich ATH! :)
Ich glaube, wir machen nächstes Jahr immer noch

tick-tock, tick-tock

:cry:

Allen einen schönen Feiertag und schönes Wochenende
Außer mir noch jemand investiert?

oder bin ich allein zurückgeblieben? :cry:
Antwort auf Beitrag Nr.: 39.651.018 von _pilot am 08.06.10 19:33:31Keine Sorge, wir sind noch da! :cool:
Antwort auf Beitrag Nr.: 39.651.018 von _pilot am 08.06.10 19:33:31@pilot. Geduld Geduld. Es ist anstrengend. Aber immer dran denken Siga ist derzeit eine 3 fache Spekulation:

- weiter schwächer werdender Euro
- Auftragserteilung Barda
- FDA Approval ST-246 Ende 2010/Anfang 2011


Hier eine aktuelle Präsentation von Siga;

http://noble.mediasite.com/mediasite/Viewer/?peid=e8203fc9c1…

Desweiteren Webinar zu Bioterror Attack:

http://www.sunherald.com/2010/06/02/2227330/bioterror-attack…

Gruß
Antwort auf Beitrag Nr.: 39.651.666 von Kleiner Chef am 08.06.10 21:03:12
ok - danke für die Infos

(will versuchen, nicht ungeduldig zu sein)
In diesem Szenario ist Siga ein Tenbagger!

This Weeks Stock Pick
6-21-2010 Stock Recommendation SIGA

While most of our recommendations are for short term swing trades, this is our first Stock of the week recommendation for a possible long term position. The current SIGA news, trend and positioning should generate a double or triple on a swing trade with the expected finalization of the BARDA contract. We see even greater long term potential for this company with worldwide distribution and an impresive pipeline. We have followed SIGA for years, since it made the transition from a small tech company to an emerging biotech. The largest stockholder of SIGA is one of the world’s most successful investors, Ron Perlman which is an indicator of the potential of this company.

Recent changes in the board of directors, the doubling of staff and other factors point to a positive outcome of the long awaited BARDA contract of over $500 million for the smallpox antiviral ST-246.

The growth of the SIGA pipeline which contains the ST-669 antiviral that recently received its first round of Government funding and in early tests is effective against over 90% of all virus strains know to exist. SIGA is also progressing on several other pipeline drugs some of which show promise as an answer to the growing problems of Lassa and Dengue fevers.
St-246 is the first antiviral drug developed using SIGA’s proprietary new technology. It has proven to be 100% effective in curing the smallpox virus. Currently our government and most others stockpile millions of doses of smallpox vaccinations. St-246 will cure smallpox for up to 2 weeks after a person is exposed to the virus whereas the current vaccinations need to be given before or immediately after exposure. Smallpox is considered to be one of the top biowarfare threats in the world and when (not if!) it is used as a weapon ST-246 will save many lives.

The share price took a hit last year when the anticipated BARDA contact did not come to fruition when expected in September and the RFP was changed. This was not a reflection on SIGA or the technology but due to bureaucratic changes that came with the new administration. With the recent hiring of key personnel for production and the addition to the board of influential insider Andy Sterns it now appears that not only will the BARDA contract be completed in the near future but that SIGA management is positioning for sale to the World Health Organization and other countries for their strategic defense stockpile programs.

The dilemma we have with SIGA is should one take profits on the announcement of the BARDA contract which we anticipate will drive the share price to our short term target of $22 or continue to hold it as other countries and the WHO come onboard with even potentially larger contacts. Our long term target for SIGA as ST-669 progresses toward FDA approval in several years is $84 at which point we anticipate a buy out or merger with major pharma.

While we anticipate trading in a range between $6 and $8 until the finalization of the BARDA contract we see the current entry point of below $7 per share is a bargain. We give the contact a 90% chance of finalization in the coming weeks or months. If for some reason this does not happen we still see the long term pipeline as enough to justify an investment in SIGA

We are Long SIGA.


Company Overview:
SIGA Technologies, Inc., a bio-defense company, engages in the discovery, development, and commercialization of products for use in defense against biological warfare agents comprising smallpox and arenaviruses. It also involves in the discovery and development of other novel anti-infectives and antibiotics for the prevention and treatment of serious infectious diseases. The company primarily offers ST-246, an orally administered antiviral drug that targets orthopox viruses. It also develops anti-arenavirus drug candidates, such as ST-294 and ST-193, which demonstrate antiviral activity in cell culture assays against arenavirus pathogens; and broad spectrum antiviral candidate, ST-669, against viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families. In addition, the company has four drug series in the pre-clinical development stage, including ST-610 and ST-148 for dengue virus of the genus Flavivirus. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York.


http://www.stocktipweekly.com/SIGA-6-21-10.htm
June 23, 2010, 8:30 a.m.
SIGA Completes Fourth Successful Human Safety Clinical Trial

NEW YORK, Jun 23, 2010 (GlobeNewswire via COMTEX) -- SIGA Technologies, Inc. /quotes/comstock/15*!siga/quotes/nls/siga (SIGA 6.85, +0.21, +3.16%) , a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today the successful completion of its fourth human clinical trial, supporting the safety and tolerability of the anticipated clinical dose of ST-246(R), SIGA's lead smallpox antiviral drug candidate. Analyses of the trial's results are consistent with findings from previous studies of ST-246 and together show that the drug will likely be found to be a safe and well-tolerated therapeutic for the treatment of orthopoxvirus infections.

The trial was conducted at three sites: Orlando Clinical Research Center (Orlando, FL), Apex Research Institute (Santa Ana, CA) and Hawaii Clinical Research Center (Honolulu, HI). A total of 107 healthy volunteers were enrolled in the study and were randomly placed into one of three different groups, each of which received either 400 or 600 mg of ST-246 or a placebo, once a day, for 14 days. All adverse events reported during the study that were considered related to ST-246 were mild to moderate. There were no severe adverse events.

"We are very satisfied with SIGA's progress in completing the studies needed to demonstrate the safety, bio-availability and efficacy of ST-246," said Dennis E. Hruby, SIGA's Chief Scientific Officer. "In addition to reaffirming the strong safety profile of ST-246, the trial results suggest an appropriate dose that we will use as we complete the remaining New Drug Application studies and a study to test its pharmacologic effects on cardiac repolarization."

"The results of this latest trial support our belief that ST-246 is likely to meet the FDA's requirements for being safe and well-tolerated. We are now in the planning stage for our expanded safety study of approximately 450 volunteers and are working with the FDA on establishing a protocol for the trial. Enrollment is expected to begin once the procedures have been determined," said Dr. Eric Rose, SIGA's Chief Executive Officer.

"As we move toward the goal of commercializing ST-246, our efforts are now directed towards completing the human and animal studies needed for regulatory approval. We are also advancing our efforts to obtain approval on additional indications for ST-246. Separately, we continue to make progress with our clinical pipeline of novel antivirals and apply for non-dilutive government grants and funding," Dr. Rose concluded.

This project was funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority, Department of Health and Human Services, in conjunction with the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200600014C.


Bei Siga kommt noch was ganz großes!!! :)
Antwort auf Beitrag Nr.: 39.727.928 von cultom4president am 23.06.10 19:19:14Gibt es einen Grund für den Anstieg heute? Kann aktuell nichts finden.

Wie schaut eigentlich die Roadmap für Siga in 2010 aus?

cultom
Antwort auf Beitrag Nr.: 39.739.760 von cultom4president am 25.06.10 20:02:27@cultom

Es gibt kein offizielles Timeschedule. Meine Einschätzung

- Es gibt als Ergebnis der vorhergehenden Meldung jetzt eine abschließende Studie für ST246
- Die könnte Ende des Jahres beendet sein
- Daran schließt sich die Einreichung bei der FDA für die Zulassung an.
- Auftragserteilung Barda kommende Wochen mit
- Kommerzialisierung und Rollout, wenn FDA Approval vorliegt

Gruß
Antwort auf Beitrag Nr.: 39.739.824 von Kleiner Chef am 25.06.10 20:17:31Anstieg ist gut aber das Volumen passt nicht....noch nicht.
Antwort auf Beitrag Nr.: 39.739.824 von Kleiner Chef am 25.06.10 20:17:31@ Kleiner Chef

Danke für deine Einschätzung!
Eine Abschlusstudie für ST246 sehe ich auch in den nächsten Wochen, wie
lange sie dauert ist ungewiss.
Der Barda-Deal liegt förmlich in der Luft, alleine die Veränderungen der letzten
Monate bei Siga deuten sehr darauf hin.

Und noch immer nur eine Handvoll Interessierte! :)

Schönes Wochenende!

cultom
Wahnsinn!

Siga ist derzeit eine extrem sichere Bank. So übersteht man hervorragend schlechte Börsen! :)

cultom

P.S: Liegt vermutlich aber auch an dem schwachen Volumen!
Antwort auf Beitrag Nr.: 39.760.888 von cultom4president am 30.06.10 23:45:01 RBC Capital expects the contract soon for SIGA 2-Jul-10 06:48 am

Siga Tech ST-246 contract expected soon, says RBC Capital
RBC Capital said said they are still waiting for a large contract for ST-246 for small pox. The firm expects an announcement over the next 2 months and there expectations are for initial sales to be $425M-$510M over a 3 year period. Shares are Outperform rated.

http://www.theflyonthewall.com/permalinks/entry.php/SIGAid12…
Die Zeit der Ruhe dürfte bald zuende sein.
Schöner Anstieg heute und sogar das Volumen zieht etwas an, sickert da etwa was durch? ;)

cultom
Die letzten Siga Tick-Tocks:

A) "We are working towards completing the human and animal studies needed for regulatory approval."

SIGA Completes Fourth Successful Human Safety Clinical Trial

NEW YORK, Jun 23, 2010 (GlobeNewswire via COMTEX News Network) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today the successful completion of its fourth human clinical trial, supporting the safety and tolerability of the anticipated clinical dose of ST-246(R), SIGA's lead smallpox antiviral drug candidate. Analyses of the trial's results are consistent with findings from previous studies of ST-246 and together show that the drug will likely be found to be a safe and well-tolerated therapeutic for the treatment of orthopoxvirus infections.

The trial was conducted at three sites: Orlando Clinical Research Center (Orlando, FL), Apex Research Institute (Santa Ana, CA) and Hawaii Clinical Research Center (Honolulu, HI). A total of 107 healthy volunteers were enrolled in the study and were randomly placed into one of three different groups, each of which received either 400 or 600 mg of ST-246 or a placebo, once a day, for 14 days. All adverse events reported during the study that were considered related to ST-246 were mild to moderate. There were no severe adverse events.

"We are very satisfied with SIGA's progress in completing the studies needed to demonstrate the safety, bio-availability and efficacy of ST-246," said Dennis E. Hruby, SIGA's Chief Scientific Officer. "In addition to reaffirming the strong safety profile of ST-246, the trial results suggest an appropriate dose that we will use as we complete the remaining New Drug Application studies and a study to test its pharmacologic effects on cardiac repolarization."

"The results of this latest trial support our belief that ST-246 is likely to meet the FDA's requirements for being safe and well-tolerated. We are now in the planning stage for our expanded safety study of approximately 450 volunteers and are working with the FDA on establishing a protocol for the trial. Enrollment is expected to begin once the procedures have been determined," said Dr. Eric Rose, SIGA's Chief Executive Officer.

"As we move toward the goal of commercializing ST-246, our efforts are now directed towards completing the human and animal studies needed for regulatory approval. We are also advancing our efforts to obtain approval on additional indications for ST-246. Separately, we continue to make progress with our clinical pipeline of novel antivirals and apply for non-dilutive government grants and funding," Dr. Rose concluded.

This project was funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority, Department of Health and Human Services, in conjunction with the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200600014C.

Forward-looking Statements

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include (i) the risk that potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (ii) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (iii) the risk that SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (iv) the risk that SIGA may not be able to secure funding from anticipated government contracts and grants, (v) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including patent protection for its products, (vi) the risk that any challenge to our patent and other property rights, if adversely determined, could affect our business and, even if determined favorably, could be costly, (vii) the risk that regulatory requirements applicable to SIGA' s products may result in the need for further or additional testing or documentation that will delay or prevent seeking or obtaining needed approvals to market these products, (viii) the risk that BARDA may not complete the procurement set forth in its solicitation for the acquisition of smallpox antiviral for the strategic national stockpile, or may complete it on different terms, (ix) the risk that third parties may protest contracts awarded to us through an RFP process which may cause such potential awards to be delayed or overturned, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA's efforts, (xi) the risk that changes in domestic and foreign economic and market conditions may adversely affect SIGA's ability to advance its research or its products, and (xii) the effect of federal, state, and foreign regulation on SIGA's businesses. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this presentation, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K, for the fiscal year ended December 31, 2009, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as of the date they are made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to publicly update any forward-looking statements whether as a result of new information, future events or otherwise.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/.

The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: SIGA Technologies, Inc.

http://investor.siga.com/releasedetail.cfm?ReleaseID=481983


B) Conference Call am 05.08. zum Q2: Hoffentlich hat Dr. Rose mehr mitzuteilen zum Barda RFP als im letzten Call zum Q1:

SIGA to Discuss Second Quarter Results of Operations on August 5, 2010

NEW YORK, Aug 2, 2010 (GlobeNewswire via COMTEX News Network) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it will report second quarter 2010 results on Thursday, August 5, 2010.

Management will host a conference call and simultaneous webcast to discuss the results of operations and provide an update on recent business developments at 4:30 P.M. ET on Thursday, August 5, 2010. Participants should call (877) 564-1219 (United States/Canada) or (973) 638-3429 (International) and request the SIGA call or provide confirmation code 90687656. A live broadcast of the call will be available on the Company's website at www.SIGA.com under the 'Events & Presentations' tab in the Investor Relations section.

A replay of the call will be available approximately two hours after the live call and will be available until 11:59 p.m. on Thursday, August 12, 2010. To listen to the replay, dial (800) 642-1687 (domestic) or (706) 645-9291 (international) and enter the pass code 90687656. The webcast of the event will also be archived on the Company's website for one year under the 'Events & Presentations' tab in the Investor Relations section.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/.

The SIGA Technologies, Inc. logo is available at www.globenewswire.com/newsroom/prs/?pkgid=4504

This news release was distributed by GlobeNewswire, www.globenewswire.com

Gruß
NEW YORK, Aug 5, 2010 (GlobeNewswire via COMTEX)

SIGA Technologies, Inc., a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced its financial results for the second quarter and first half ended June 30, 2010.

For the second quarter of 2010, revenues were $4.4 million compared to $4.0 million in 2009, and operating loss was $3.0 million compared to $2.6 million in 2009. Net loss per share for the three month periods ending June 30, 2010 and 2009 was $0.10 and $0.28, respectively.

For the first half of 2010, revenues were $9.5 million compared to $5.9 million in 2009, and net operating loss was $6.0 million compared to $5.5 million in 2009. Net loss per common share was $0.21 compared to $0.47 in 2009.

"We continued to take steps toward our goal of commercializing ST-246(R), as well as make progress in the development of our pipeline of drug candidates. Our Dengue fever, Lassa fever and broad spectrum antiviral programs continue to advance in line with our expectations," stated Ayelet Dugary, SIGA's Chief Financial Officer. "Our laboratory space was recently remodeled with enhanced analytical and screening capabilities that we expect will help accelerate our drug development efforts in the future."

Q2 and First Half 2010 Key Financial Results

Revenues

Revenues from research and development grants and contracts in the second quarter of 2010 were $4.4 million compared to $4.0 million in the second quarter of 2009. The increase of $0.4 million or 11% mainly relates to $0.96 million of revenue generated from our grant and contract for the development of a broad spectrum antiviral drug, an increase of $0.55 million in revenue generated from our grants for the development of drug candidates for arenavirus pathogens, and a decrease of $1.1 million in revenue generated from programs supporting the advanced development of ST-246.

For the six months ended June 30, 2010 and 2009, we recorded revenues of $9.5 million and $5.9 million, respectively, an increase of $3.6 million or 60%. Revenues generated from grants and contracts supporting the development of ST-246 increased $1.7 million, revenues related to our arenavirus pathogen program increased $0.52 million, and $1.3 million of the increase was recognized from our new grant and contract for the development of a broad spectrum antiviral drug.

Research and Development

Research and development expenses in the second quarter in 2010 and 2009 were $4.9 million and $4.7 million, respectively. For the six months ended June 30, 2010 and 2009, we incurred $10.8 million and $7.4 million, respectively, in research and development expenses, an increase of $3.4 million or 46%. For the six-month period, expenditures related to the continued development of ST-246 and its alternative formulations, including costs associated with our commercial validation campaign, increased $1.9 million. Moreover, costs related to the development of our broad spectrum antiviral drug and our arenavirus pathogens programs increased $0.43 million and $0.39 million, respectively.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $2.2 million compared to $1.8 million in the second quarter of 2009. For the first six months ended June 30, 2010 and 2009, selling, general and administrative expenses were $4.2 million and $3.9 million, respectively. Higher selling, general and administrative costs in 2010 mainly relate to increases in insurance premiums, legal costs, and employee-related expenses including stock-based compensation.

Patent Preparation Expenses

Patent expenses were $0.31 million and $0.63 million for the three and six months ended June 30, 2010, respectively. The increases of $0.22 million and $0.43 million from the comparable periods in 2009 reflect reinforced efforts to protect our lead drug candidates in expanded geographic territories.

Financial Condition and Liquidity

Cash, cash equivalents and short-term investments on June 30, 2010 were $15.3 million, compared to $19.5 million on December 31, 2009. Additionally, our accounts receivable balance on June 30, 2010 was $3.4 million, which is primarily comprised of balances due for expanded research and development activities performed in May and June, 2010.
hallo freunde der nacht!?
vielleicht klappts jetzt doch noch
gamz frisch aus dem netz

Wedbush rated Siga Technologies Inc. (NASDAQ: SIGA) to Outperform with price target $15

http://www.gainerstoday.com/Article-74931
Wedbush Starts SIGA (SIGA) at Outperform; Expects Award from BARDA for Smallpox Countermeasure

More News related to SIGA
Wedbush Starts SIGA (SIGA) at Outperform; Expects Award from BARDA for Smallpox Countermeasure
SIGA Technologies Reports Financial Results for the Second Quarter and First Half of 2010
SIGA to Discuss Second Quarter Results of Operations on August 5, 2010
SIGA Tech. (SIGA) Announces Addition of Andy Stern to Board
SIGA Technologies (SIGA) Revises Q110 Loss to $0.10/Share, Compared to an EPS of $0.10
More News related to SIGA
More News related to New Coverage
Wedbush Assumes Coverage on Cadence Pharma (CADX) with an Outperform
Wedbush Starts SIGA (SIGA) at Outperform; Expects Award from BARDA for Smallpox Countermeasure
Standpoint Research Initiates Coverage on The Buckle (BKE) with a Buy; Bad News Priced In, Rebound Not
Standpoint Research Starts The Buckle (BKE) at Buy
Dougherty & Co Initiates Coverage on Zoll Medical (ZOLL) with a Buy
More News related to New Coverage
September 10, 2010 2:03 PM EDT

Shares of SIGA Tech. (Nasdaq: SIGA) have surged nearly 7% in mid-day trading following a bullish analyst note from Wedbush. The firm initiated coverage on the stock with an Outperform rating and a $15 fair value estimate.

Wedbush believes that SIGA will soon "receive an award from BARDA for the procurement of a smallpox therapeutic medical countermeasure", placing the initial total value at $255 million, "with a potential follow-on for a further 12 million courses..." valued at $1.8 billion.

With shares of SIGA last trading at $8.10, the firm's new price target implies potential upside of about 85%.

http://www.streetinsider.com/New+Coverage/Wedbush+Starts+SIGA+(SIGA)+at+Outperform;+Expects+Award+from+BARDA+for+Smallpox+Countermeasure/5960561.html
Antwort auf Beitrag Nr.: 40.134.976 von mrsun am 10.09.10 21:16:55Ja, der Kursverlauf heute war eine schöne Überraschung. Auch das Volumen konnte sich sehen lassen. Ist eben nur eine Frage der Zeit bis man auf diese Aktie aufmerksam wird.

Mal schauen ob die nächsten Wochen mehr Infos zum BARDA-Deal bringen.

cultom
Antwort auf Beitrag Nr.: 40.135.590 von cultom4president am 10.09.10 23:38:28Siga: Tick-Tock - Sekunden vor Zwölf?

Nicht neu - aber aktueller denn je:


6-21-2010 Stock Recommendation SIGA

While most of our recommendations are for short term swing trades, this is our first Stock of the week recommendation for a possible long term position. The current SIGA news, trend and positioning should generate a double or triple on a swing trade with the expected finalization of the BARDA contract. We see even greater long term potential for this company with worldwide distribution and an impresive pipeline. We have followed SIGA for years, since it made the transition from a small tech company to an emerging biotech. The largest stockholder of SIGA is one of the world’s most successful investors, Ron Perlman which is an indicator of the potential of this company.

Recent changes in the board of directors, the doubling of staff and other factors point to a positive outcome of the long awaited BARDA contract of over $500 million for the smallpox antiviral ST-246. The growth of the SIGA pipeline which contains the ST-669 antiviral that recently received its first round of Government funding and in early tests is effective against over 90% of all virus strains know to exist. SIGA is also progressing on several other pipeline drugs some of which show promise as an answer to the growing problems of Lassa and Dengue fevers.

St-246 is the first antiviral drug developed using SIGA’s proprietary new technology. It has proven to be 100% effective in curing the smallpox virus. Currently our government and most others stockpile millions of doses of smallpox vaccinations. St-246 will cure smallpox for up to 2 weeks after a person is exposed to the virus whereas the current vaccinations need to be given before or immediately after exposure. Smallpox is considered to be one of the top biowarfare threats in the world and when (not if!) it is used as a weapon ST-246 will save many lives.

Update: 6-23 Breaking News today of SIGA's successful completion of another round of safety trials moves them one step closer to An FDA NDA. This may move the timeline from 2011 back into late 2010. While FDA approval IS NOT needed for the BARDA contract some foreign countries will want this in place before purchasing St-246. From an income perspective the eventual FDA approval will open the door to possibly millions of courses being sold to institutions and private companies in the US as well as being used as an adjunct therapy for vaccinations.

The share price took a hit last year when the anticipated BARDA contact did not come to fruition when expected in September and the RFP was changed. This was not a reflection on SIGA or the technology but due to bureaucratic changes that came with the new administration. With the recent hiring of key personnel for production and the addition to the board of influential insider Andy Sterns it now appears that not only will the BARDA contract be completed in the near future but that SIGA management is positioning for sale to the World Health Organization and other countries for their strategic defense stockpile programs.

The dilemma we have with SIGA is should one take profits on the announcement of the BARDA contract which we anticipate will drive the share price to our short term target of $22 or continue to hold it as other countries and the WHO come onboard with even potentially larger contacts. Our long term target for SIGA as ST-669 progresses toward FDA approval in several years is $84 at which point we anticipate a buy out or merger with major pharma.


While we anticipate trading in a range between $6 and $8 until the finalization of the BARDA contract we see the current entry point of below $7 per share is a bargain. We give the contact a 90% chance of finalization in the coming weeks or months. If for some reason this does not happen we still see the long term pipeline as enough to justify an investment in SIGA

We are Long SIGA.

http://www.stocktipweekly.com/SIGA10.htm


Fazit:

Im September werden viele öffentliche Entscheidungen aufgrund der Haushaltslage getroffen (Ende Fiskaljahr 09.2010). Dies könnte auch auf Siga und dem Barda Auftrag zutreffen. Würde genau in die Timeline mit dem erwarteten FDA-Approval in 2011 passen.

Wenn es weiterhin so rasant mit Siga zugeht, dann knacken wir in dieser Woche das All-Time-High!
Bin gespannt ob im September irgendeine Entscheidung fällt. Das Volumen zieht merklich an, die Aktie will nach oben.

cultom
Antwort auf Beitrag Nr.: 40.142.106 von cultom4president am 13.09.10 16:04:02Schaut heute ein wenig nach Konsolidierung aus. Die letzten Tage ging es ja stark nach oben. Es würde mich trotzdem nicht wundern wenn wir leicht Null auf Null schliessen würden. Das Volumen schaut sehr gut aus, wird heute wieder über dem Durchschnitt liegen.

September ist ja nicht mehr ganz so lang!
mühsam ernährt sich das Eichhörnchen

ne echte Geduldsprobe, dieser Wert

seid ihr alle noch positiv gestimmt?
Antwort auf Beitrag Nr.: 40.292.485 von _pilot am 08.10.10 21:36:35Richtig: Und das Eichhörnchen hat schon
gesammelt um den Winter zu überbrücken.
Wer den Anlagehorizont bis ins nächste
Frühjahr mitbringt sollte belohnt werden.
Mit etwas Glück beginnt man dann die
FDA-Zulassung einzupreisen. Wenn diese
kommt gilt: Only the sky is the limit.

Gruß
Antwort auf Beitrag Nr.: 40.293.473 von Kleiner Chef am 09.10.10 11:25:01SIGA ROCKT!!!!!!!

SIGA Selected for the Procurement of Smallpox Antiviral Drug for the Strategic National Stockpile and Responds to Small Business Size Protest
SIGA Selected for the Procurement of Smallpox Antiviral Drug for the Strategic National Stockpile and Responds to Small Business Size Protest
Oct. 13, 2010 (GlobeNewswire) --
NEW YORK, Oct. 13, 2010 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that the U.S. Department of Health and Human Services (HHS) has announced HHS's intention to make an award to SIGA of a contract to deliver 1.7 million courses of its smallpox antiviral for the Strategic National Stockpile, pending resolution of issues relating to SIGA's status with the Small Business Administration. The award relates to a Request for Proposal issued by HHS's Biomedical Advanced Research and Development Authority (RFP-BARDA-09-35). The base contract, if finalized, is expected to generate revenues of approximately $500 million, and the entire contract, if all options are exercised, is expected to generate revenues of approximately $2.8 billion.

The Small Business Administration issues noted above derive from HHS notification to SIGA that Chimerix, Inc. (Chimerix) has filed a small business size protest against SIGA after receiving pre-award notice from HHS that Chimerix was an unsuccessful bidder. HHS designated the proposed contract as a small business set-aside at the time of the original solicitation in March 2009. SIGA intends to respond promptly to the Small Business Administration concerning Chimerix's protest.

Dr. Eric A. Rose, SIGA's Chairman and Chief Executive Officer, stated, "We are very proud that HHS has selected our groundbreaking drug, ST-246®, for this important acquisition and believe that SIGA appropriately qualified as a small business concern for this procurement."

Details of HHS's March 11, 2009 request for proposal and subsequent amendments can be found on the Federal Business Opportunities website at www.fbo.gov/index?s=opportunity&mode=form&id=61e7acbe316f2c52bfe0cc8c4b4852fd&tab=core&_cview=1. SIGA expects the proposed contract to be executed following resolution of the Chimerix protest; however, there can be no assurance concerning the outcome of the small business size protest.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/.

The SIGA Technologies, Inc. logo is available at www.globenewswire.com/newsroom/prs/?pkgid=4504

Forward-looking Statements

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding SIGA's ability to offer its products for sale to the U.S. government and statements regarding execution of the contract described above or the timing or outcome of the pending protest. Statements other than statements of historical fact are forward-looking statements, and may be identified by, among other things, forward-looking language such as the words or phrases "expect," "intend," "believe," "anticipate," "estimate," "may," "project," "scheduled to," "seek," "should," "would," "will be," "will continue," "will likely result," "targeted," or the negative of those terms, or other similar words and phrases or by discussions of intentions or plans. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include (i) the risk that potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (ii) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (iii) the risk that SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (iv) the risk that SIGA may not be able to secure funding from anticipated government contracts and grants, (v) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including patent protection for its products, (vi) the risk that any challenge to our patent and other property rights, if adversely determined, could affect our business and, even if determined favorably, could be costly, (vii) the risk that regulatory requirements applicable to SIGA's products may result in the need for further or additional testing or documentation that will delay or prevent seeking or obtaining needed approvals to market these products, (viii) the risk that BARDA may not complete the procurement set forth in its solicitation for the acquisition of smallpox antiviral for the strategic national stockpile, or may complete it on different terms, (ix) the risk that the pending protest or another future protest may cause a contract award to us through the RFP process to be delayed or overturned, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA's efforts, and (xi) the effect of federal, state, and foreign regulation on SIGA's businesses. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as of the date they are made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to publicly update any forward-looking statements whether as a result of new information, future events or otherwise.

CONTACT: KCSA Strategic Communications
Todd Fromer
212-896-1215
Tfromer@kcsa.com
Marybeth Csaby
212-896-1236
mcsaby@kcsa.com
danke denen, die mir geholfen haben, hier investiert zu bleiben:

K C und c4p

:kiss:
Antwort auf Beitrag Nr.: 40.315.892 von _pilot am 13.10.10 19:50:07Wunderbar!

Das Puzzle ist so langsam komplett. :)
Kaum einer hat Siga in Deutschland auf seiner Watchlist, wird der erste Teil des Deals abgewickelt, werden viele Börsenblätter aufspringen.

Und wir sind alle schon vorher investiert gewesen.

cultom

P.S: Durchhalten ist weiterhin angesagt, Marktcap von 1Mrd. ist das nächste Zwischenziel! ;)
Antwort auf Beitrag Nr.: 40.316.043 von cultom4president am 13.10.10 20:08:58THX
:)
Was für ein Handelstag, SIGA schliesst mit einem Plus von 45,68% bei 12,47USD.
Das Volumen betrug sagenhafte 7.95Millionen (275,000.00 durchschnittlich).
Und in Deutschland interessierte dies 3 Leute! ;)

Bin gespannt was der Chef dazu sagt, ich verabschiede mich für heute!

cultom
Antwort auf Beitrag Nr.: 40.317.099 von cultom4president am 13.10.10 22:06:27Noch ganz schnell, hat jemand eine Einschätzung zu PharmAthene.
SIGA und PharmAthene wollten im Oktober 2006 fusionieren, SIGA cancelte den Deal im Dezember. Könnte es sein das PharmAthene sich vom BARDA-Kuchen ein Stück holen wird?
Im Endeffekt kosten die ja auch nur 60Mio derzeit. :)
Der Kurs von PharmAthene zog ja auch schon gut an.

So als Anregung.

cultom
Antwort auf Beitrag Nr.: 40.317.314 von cultom4president am 13.10.10 22:34:51Servus Miteinander,

hier eine interessante Spekulation zu PharmAthene:

http://www.benzinga.com/general/10/10/526235/can-pharmathene…

Angeblich hatte PharmAthene die Marketing und Vertriebsrechte an ST-246 erworben.
Dies werden nun die Gerichte klären.

Allen einen schönen Wochenstart!

cultom
Antwort auf Beitrag Nr.: 40.317.099 von cultom4president am 13.10.10 22:06:27@Cultom: Wenn man aus dem sonnigen Süden kommt
und findet diese Entwicklung kann ich nur sagen:

Ich bin entzückt.....:p


Gruß
@ Kleiner Chef,

mal schauen was die Zahlen heute so bringen, dies erwarten ja die werten Herren Analysten:

Analysts, on average, expect SIGA Technologies (NASDAQ:SIGA) to report a loss of $0.08 per share on sales of $5 million on November 02, 2010.
For the full year, analysts expect the company to post a loss of $0.37. In the year-ago period, the company reported a loss of $0.04 on sales of $4 million.
In the previous quarter, the company reported a loss of $0.10, missing consensus estimates for a loss of $0.08.



Ich glaube viel wichtiger sind die Aussagen zum weiteren Stand des BARDA-Deals. Darauf wird sicher die eine oder andere Frage im Conference Call abziehen.

cultom
Die Zahlen sind raus!


NEW YORK, Nov 2, 2010 (GlobeNewswire via COMTEX) -- SIGA Technologies, Inc., a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today reported its financial results for the third quarter and the nine months ended September 30, 2010.

Revenue for the third quarter of 2010 was $6.6 million compared to $3.9 million in 2009, and operating loss was $2.4 million compared to $2.6 million in 2009. Net loss per share for the three-month periods ending September 30, 2010 and 2009 was $0.10 and $0.03, respectively.

For the nine months ended September 30, 2010, revenue was $16.2 million compared to $9.9 million in 2009, and net operating loss was $8.5 million compared to $8.1 million in 2009. Net loss per common share was $0.33 compared to $0.59 in 2009.

Third Quarter and Nine Months 2010 Key Financial Results

Revenues

For the third quarter of 2010, revenue from research and development ("R
Antwort auf Beitrag Nr.: 40.441.319 von cultom4president am 02.11.10 23:14:27Hi c4p und K C,

warum geht der Kurs runter?

Waren die Zahlen nicht gut?
Oder wurden sie besser erwartet?

Schönen Abend noch! Grüße.

_pilot
Antwort auf Beitrag Nr.: 40.449.349 von _pilot am 03.11.10 21:45:31Hi Pilot,

erwartet wurde ein Quartalsverlust von 8 USCent/Aktie und Siga hatte 10 USCent/Aktie geliefert.
War heute ein Rückgang unter sehr hohem Volumen, ich denke das in den kommenden Tagen die 13USD wieder möglich sind.

cultom
Antwort auf Beitrag Nr.: 40.449.349 von _pilot am 03.11.10 21:45:31Ich habe den Conference Call bisher nicht
angehört. Derzeit sind folgende Themen für Siga
relevant:

a) SBA-Issue ==> Chimrex hat moniert, daß Siga die Vorrausetzungen der Unternehmensgröße nach für den Barda Contract nicht erfüllt ==> Dieser Unsicheheitfaktor sollte aber
kurzfristig zugunsten von Siga entschieden werden
b) PIP meldet ja Ansprüche an Siga auf dem Rechtsweg an (alter Merger, der von SIGA verworfen wurde) ==> schafft Unsicherheit
c) FDA-Timeline für ST-246 ==> mein Stand ist ein Approval in 2011. Verschiebt der sich nach hinten?
d) Barda Contract hängt von a) ab. Wenn SBA Issue geklärt, sollte der Barda-Contract über 2,8 Mrd. Dollar Gesamtumfang wieder in den Vordergrund rücken.

Fazit: Es gibt einige Punkte der Unsicherheit, die zum Anlass für Gewinnmitnahmen führen.
Dennoch kann es ganz schnell wieder in die andere Richtung gegen, wenn das SBA-Issue von Chimrex abgewiesen wird.

Gruß


Wedbush comments 3-Nov-10 02:33 pm 13:52 SIGA SIGA Technologies: Shares to trade sharply up on the news of a positive resolution of the SBA issue - Wedbush (12.63 +0.92)Wedbush notes the BARDA contract remains pending, awaiting the determination of the Small Business Administration (SBA) appeal launched by Chimerix. Firm expects that the most likely outcome is that the SBA will find that SIGA was a small business. Failing that, firm believes that SIGA's smallpox medical countermeasure is of sufficient national importance that the contracting officer will make a determination that issuing the contract is in the government's best interests from a national security perspective. Firm expects the stock to trade sharply up on the news of a positive resolution of the SBA issue, and reiterates their Outperform rating and $15 price target.
Antwort auf Beitrag Nr.: 40.449.907 von cultom4president am 03.11.10 23:01:18das ging ja schneller als gedacht
:)

danke euch beiden - ihr habt es wirklich drauf!
Ich glaube man sollte seine Position zu SIGA eventuell neu überdenken:

BOSTON (MarketWatch) — Shares of SIGA Technologies Inc. sank Monday as the drug sector’s two main indexes moved south.

(SIGA 11.84, -1.38, -10.45%) shares were off 15% at $11.28.

Over the weekend, SIGA said it may lose a government contract worth up to $2.8 billion for its smallpox medication because the Small Business Administration has determined it does not qualify as a small business. The smallpox contract was to be awarded to a small business under the original proposed contract by the Department of Health and Human Services.

SIGA said it plans to appeal the SBA ruling.

@ Kleiner Chef,

da hatte anscheinend Chimrex doch etwas mehr Erfolg gehabt. Bin gespannt wie die Sache ausgeht. Da ich ab Freitag für 3 Wochen nach Vietnam fliege werde ich wohl recht schnell mich entscheiden müssen. Im Moment eine ziemlich verzwickte Situation.
Antwort auf Beitrag Nr.: 40.475.826 von cultom4president am 08.11.10 17:16:36^RBC-Analyst Statement:

Siga Technologies plunges on contract reversal
Gov't finds Siga Technologies ineligible for smallpox contract, sending shares tumbling


ShareretweetEmailPrintCompanies:SIGA Technologies, Inc. Related Quotes
Symbol Price Change
SIGA 11.94 -1.28

{"s" : "siga","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} On Monday November 8, 2010, 12:03 pm
NEW YORK (AP) -- Shares of Siga Technologies Inc. declined Monday after the company said a federal agency determined it is not eligible for small business assistance, meaning it may not receive a smallpox treatment contract worth up to $2.8 billion.

Siga's shares plunged as much as 22.5 percent in morning trading.

Last month, the U.S. Department of Health and Human Services said it intended to give Siga a contract to deliver 1.7 million doses of smallpox treatment. The deal was worth $500 million, with options that could have increased its value to $2.8 billion. A competitor protested the award.

Siga said Sunday that an office within the Small Business Administration determined the company is not a small business. Siga plans to appeal the decision, and will continue developing the smallpox treatment, which is called ST-246.

According to Siga's latest annual report, which was filed in March, the company had 55 full-time employees. Its market capitalization of $663 million as of Friday.

The protest, which was filed by Chimerix Inc., is based on the company's size as of March 2009. Siga had 43 employees at the time.

RBC Capital Markets analyst Jason Kantor said he thinks Siga will ultimately get the contract. He said Siga is still small enough to meet the Small Business Administration's standards. The SBA may have based its decision on Siga's relationship with MacAndrews & Forbes Holdings Inc., a much larger holding company run by billionaire investor Ronald Perelman. As of March 2009, MacAndrews & Forbes owned 13.4 percent of Siga, he said.

Siga shares fell $1.39, or 10.5 percent, to $11.83 in midday trading. The shares are up 54.4 percent since Oct. 12, the day before the award was announced. The stock jumped 45.7 percent


http://finance.yahoo.com/news/Siga-Technologies-plunges-on-a…
Gruß
08.11.2010 16:09
SIGA shares plummet as govt contract faces ineligibility risk


...Noble Financial Capital Markets analyst Raghuram Selvaraju said he does not expect the authority to invalidate the award based on SBA's decision but might give some benefit to Chimerix as well.

'The fact that SIGA is or is not a small business does not negate the fact that there is a major unmet need for anti-smallpox therapeutic and prophylactic agents and the fact that SIGA's drug is the only treatment that has shown to be effective.'
http://www.finanznachrichten.de/nachrichten-2010-11/18481341…

Also abwarten und Tee trinken? Muss wohl jeder selbst entscheiden.





Now what: Rival Chimerix is the company bringing up the complaint, but I have to wonder how small can a business be to fill a $500 million base contract that could be worth as much as $2.8 billion? The contract may be amended, but I think shares will recover later in the day because SIGA will likely not lose the entire contract. I'm buying today's drop and think shares will recover once this storm blows over.
http://www.fool.com/investing/general/2010/11/08/siga-techno…
Antwort auf Beitrag Nr.: 40.478.042 von Mandala64 am 08.11.10 20:53:34Das Ganze aus der Sicht von Chimerix:

Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
Posted : Mon, 08 Nov 2010 03:34:47 GMT
Author : Chimerix, Inc.
Category : Press Release
der vollständige Artikel:
http://www.earthtimes.org/articles/press/smallpox-broad-spec…
Wahnsinn der Rebound heute, auch das Volumen sehr vielversprechend.
Siga steht und fällt mit diesem Deal. Es gilt erstmal weiter das Geschehen zu beobachten.

Schauen wir mal wie schnell die Unsicherheit aus dem Markt ist.

cultom
Antwort auf Beitrag Nr.: 40.478.627 von cultom4president am 08.11.10 21:58:45Cultom: Siga fällt nicht - kurzfristig ist einiges denkbar - siehe gestern.
Siga fällt langfristig nicht, da der Deal nur an Siga gehen kann, es gibt keine Produktalternative. Die Frage ist nur wann er zustande kommt. Die beiden Klagen stehen im Raum, das ist richtig. Aus meiner Sicht ist das SBA-Issue ein Witz, hier mit Perelmann zu argumentieren. Wenn ein Unternehmen wie SIGA mit 50 MA nicht unter Small-Business-Unit läuft für 2,8 Mrd. Umsatzvolumen, dann feiere ich demnächst Weihnachten im Frühjahr zu Ostern!

Die zweite Rechtsklage des von Siga gekündigten Mergers, bei nicht unterschriebenen
Verträgen, hat im Innenverhältnis SIGA und PIP eine Relevanz, nicht aber auf das Zustandekommens des
a) Barda-Auftrages von 2,8 Mrd. und
b) FDA-Zulassung

Gruß
eh wie geil,

habe den titel seit Nov. 2008 im Depot und total verpennt. habe das ding bei 2,27 usd gekauft. geht es noch weiter hoch?
Antwort auf Beitrag Nr.: 40.487.789 von Klabusterbeeren am 09.11.10 21:26:34habe den titel seit Nov. 2008 im Depot und total verpennt.

Bist ja n richtiger Scherzkeks!
Antwort auf Beitrag Nr.: 40.478.627 von cultom4president am 08.11.10 21:58:45dir erstmal einen schönen Urlaub !!!
Antwort auf Beitrag Nr.: 40.481.945 von Kleiner Chef am 09.11.10 11:54:12Servus Zusammen,

nach genauer Recherche finde ich es wahnwitzig worauf sich die SBA bei ihrer Begründung beruft. Kurzfristig wird es hier recht angespannt bleiben.

Ich belasse meine Position vorerst bei voller Anzahl. Melde mich hiermit aus dem Forum für 3 Wochen ab, passt ein wenig auf die Siga auf. :)

Bis dahin.

cultom
,
SIGA Comments on U.S. Government Survey on Smallpox Antiviral Acquisition

NEW YORK, Nov. 18, 2010 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA - News), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, noted today that the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority ("BARDA") has announced a market survey to determine whether there is sufficient capacity among qualified small businesses to supply smallpox antiviral using the small business set-aside mechanism.



"The U.S. Government's announcement reaffirms its commitment to acquire a smallpox antiviral for the protection of the U.S. population against the 'material threat' of a possible bioterrorism smallpox attack," stated Dr. Eric A. Rose, SIGA's Chairman and Chief Executive Officer.

Dr. Rose continued, "We believe that the market survey will demonstrate that a smallpox antiviral acquisition should not proceed as a small business set-aside. SIGA also believes that it best satisfies all of the criteria of the market survey but for the recent Small Business Administration ruling that we intend to appeal. If the current BARDA process confirms that SIGA is the only supplier that can meet the requirements for this biodefense countermeasure, and the only supplier capable of delivering the requested 1,700,000 courses of therapy in a timely manner, then BARDA may abandon the small business set-aside and adopt a different contracting mechanism. SIGA stands ready to meet the needs of the Strategic National Stockpile."


Siga Technology: "The high uncertanty and low risk investment"!

Investment Analysis: SIGA Technologies (SIGA)

The investment analysis below is our ninth in our ongoing series of guest write-ups, and is brought to you by friend of the blog Ryan Morris. Ryan is managing partner at Meson Capital, a focused, value oriented hedge fund based out of New York/Toronto (we would note that Ryan is also a Contributor at Sum Zero, a member of both VIC and DDIC, as well as the newest “value voice” at the fantastic CGI Value). Meson was formed in February 2009 and has returned north of 400% net to partners since its inception (fwiw, we actually had to rub our eyes a bit the first time we saw it, incredible no?). Anyhow, we found Ryan's write-up on current AAOI Partners Fund holding SIGA Technologies (SIGA) to be not only cogent and concise, but particularly timely given the companies recent developments and the minimal reaction to what was undoubtedly a game changing event for the company and its future.

With SIGA (much like we saw recently with Premier Exhibitions) Mr. Market appears to be temporarily asleep at the wheel yet again, as a recently awarded government contract should have (but luckily did not as of yet) driven the companies shares substantially higher. Call us crazy, but when a company is awarded an enormous contract worth potentially multiples of its current stock price and the stock barely reacts, an incredible mis-pricing – and therefore opportunity – has just occurred. Not that we're complaining btw (we'll take it ), we just can't help being a little shocked by both the frequency and magnitude of the the markets myopia on occasion. Regardless, one things clear, situations like this are the type of low-risk, high-return investment opportunities that we as investors live for. We think you'll agree.

Enjoy!

Thesis:

SIGA is a biotech that has recently jumped but similarly to GYRO or PRXI it has been largely de-risked from an anticipated contract pre-announcement but still presents a 2-3X upside due to significant uncertainty in the end result. This uncertainty is only perceived risk as the situations that justify a stock price lower than the current $12.10 seem extremely unlikely. The near-term uncertainty is being caused by two lingering lawsuits that should be cleared up in the next 3-6 months which I believe are both baseless and in the worst case immaterial to the main thesis. It's a classic high-uncertainty, low-risk situation.

The primary thesis is that BARDA has pre-announced that they are going to award a contract to SIGA for up to $2.8B for smallpox treatment ST-246 (not vaccine, the stockpile already has vaccine, this is the only known cure for smallpox, it's impressive innovation) for the national stockpile. The first, almost-confirmed batch is for 1.7M doses at $300M/dose for about $500M at first with follow on options (at lower $/dose) up to $2.8B. This is a contract that has already been announced and assumes zero value for international orders or other products – they are working on other drugs and from what I understand have made good progress on an anthrax treatment.

The valuation is subject to great uncertainty of course because we don't know how many options will be exercised by the BARDA contract. At 46M shares out now it seems pretty easy to get to a $30 stock price just from this one contract and potentially much higher with international orders and the potential value of the rest of their pipeline.

There is one other competitor who is working on a serious treatment for smallpox, CMX-001 from Chimerix. They were not awarded the contract as the RFP from BARDA required a primate effectiveness study and they did not have one yet. This is all part of an initiative created in 2004 called Project BioShield which was reiterated in Obama's 2010 State of the Union speech:

http://www.bioprepwatch.com/news/211804-president-speaks-of-new-bioterro....

So I expect there is some imminence to this and they don't intend to wait for a competitor for several more years to create the stockpile. The stockpile needs to be renewed continually as drugs expire, so there is room in the market for two competitors going forward and I wouldn't be surprised to see Chimerix and SIGA both in the program 5 years from now, though I don't have any insight into how effective Chimerix's treatment is, while SIGA's is solidly proven already.

The two (dumb) lawsuits creating near term uncertainty are:

1) Competitor Chimerix filed a complaint with the SBA that SIGA should not be considered a small business despite the fact that it has 55 employees and <30M in revenue because Ron Perelman through MacAndrews & Forbes owns a significant amount (about half) of the company and so they think it should be considered an affiliate. The SBA amazingly just recently ruled in favor of this reasoning which is why the stock dropped 20% on Monday morning (though finished the day only down 5% or so). The company announced that they are working on multiple ways around this, the obvious and easy thing would be if Perelman just reduced the stake but I don't think he will have to. For one, while the RFP was a small business set aside there was no reason that it had to be. The main thing though is that this is a smallpox treatment, it's hard, it's not contracting out paving a road or something. If a technicality based on someone owning 45% vs 30% of a company prevents the country from being protected from smallpox, I'm moving to one of Peter Thiel's seasteading countries or something. I just don't think something that obviously dumb can happen in this country, but I'm an optimist!

2) PharmAthene (PIP) is suing SIGA essentially for a cut of the contract because in 2006 they had a potential merger that fell apart and PIP was supposed to get distribution rights to ST-246. From my understanding all of the documents from 2006 said “non-binding” on every page and even in the worst possible case and PIP won and got a cut as much as they might have in distribution, it seems like it would be a 10% expense, so for a stock with 2-3X upside it's not meaningful enough to change the equation. My personal interpretation on the issue is that PIP was hoping to get a pound of flesh in a settlement (but SIGA said on their recent CC that they don't intend to settle and will go to trial) or get their stock price up so they could raise more money – which actually did just happen. Now that PIP isn't in a desperate, cash-poor situation due to their recent SIGA-news-assisted capital raise, I would expect them not to fight to the death over something they're probably going to lose anyways.

Coat-tailing Ron Perelman is no longer a major part of the thesis, as it was before the contract was pre-announced (I should say announced but until the SBA deal is settled it is just an intended award). However, it is comforting that he is involved as I doubt he'd ever be hurt by what seem like very weak lawsuits whereas a company with weaker backers may have to compromise on pricing or a rich settlement.

Variant View

The contract has still not technically been awarded, BARDA has only stated their intent to give the award. The recent SBA determination http://www.fiercebiotech.com/story/wsj-sigas-billionaire-owner-could-der... has given a nice entry point and is a problem that should be able to be dealt with fairly swiftly. It seems extremely unlikely that a technical hiccup derails the whole process and forces the US to wait an extra several years for protection from smallpox when it was spoken about in the current year's state of the union address.

Update (Nov 23, 2010):

On November 18 (i.e., immediately after Ryan wrote the above thesis), SIGA released the following press release that indicates the end game here will likely be a function of BARDA simply having the small business set aside removed from the contract. This conclusion is further bolstered by a close reading of BARDA's recently released RFI. Honestly, it doesn't take a genius to read between the lines here and realize that both the recent press release and RFI (both of which are embedded below) are meaningful signal's that SIGA's contract issues will are likely to be resolved within the next few months.


SIGA Press Release (11/18)

Request For Information (RFI)

Attached below is the RFI that BARDA issued last week to request information on whether or not any small businesses can fulfill the smallpox contract requirements. We would note that this is pretty tightly written around SIGA as the only possible candidate (i.e., it discusses manufacturing capabilities and increases importance of the primate study – both capabilities that Chemerix almost certainly does not possess at this point) and that it has a deadline for responses by November 29 (i.e., a very short turnaround). Again, a considerable amount of anecdotal evidence (and a little common sense) suggests that Chemerix is years away from meeting the RFI's requirements, and hence that SIGA is the only company capable of delivering on the BARDA contract at this point time.

Special Notice No.: SS BARDA 2010 Small Pox Antiviral's



Read more: http://www.benzinga.com/10/11/635193/investment-analysis-siga-technologies-siga#ixzz16BtZauPS
Delaware Court Denies SIGA's Motion for Partial Summary Judgment in its Entirety

PharmAthene's Breach of Contract Lawsuit Against SIGA Technologies to Proceed to Trial Starting January 3, 2011
Nov. 24, 2010 (PR Newswire) --

ANNAPOLIS, Md., Nov. 24, 2010 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that the Delaware Court of Chancery has issued a ruling denying in full SIGA Technologies' motion for partial summary judgment in PharmAthene's breach of contract lawsuit against SIGA. Trial on all counts in PharmAthene's complaint in this case is set to commence on January 3, 2011.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, there can be no assurance that the Company will prevail in its lawsuit against SIGA or that even if the court rules in the Company's favor the court will award monetary damages or other remedies adequate to fully compensate the Company for its loses.

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.

SOURCE PharmAthene, Inc.



Source: PR Newswire (November 24, 2010 - 10:33 AM EST)
A Closer Look at PharmAthene and Their Pending Lawsuit Against SIGA Technologies

Dec. 3, 2010 (Marketwire) --

LOS ANGELES, CA -- (Marketwire) -- 12/03/10 -- PharmAthene, Inc. (NYSE Amex: PIP), the biodefense company developing medical countermeasures against biological and chemical threats, has been making headlines on Wall Street after filing a breach of contract lawsuit against SIGA Technologies Inc. Their case is set to begin Jan. 3 despite the fact that SIGA tried twice to dismiss the case or portions of the case. Just days ago, the Delaware Court of Chancery issued a ruling denying in full Siga Technologies' motion for partial summary judgment.

In play is the fact that SIGA was initially awarded a big contract through BARDA (The U.S. Biomedical Advanced Research and Development Authority) that could be worth $2.8 billion.

Who is PharmAthene and why do they feel they may be entitled to damages in their upcoming case against SIGA?

In an exclusive interview, Eric I. Richman, the President and Chief Executive Officer of PharmAthene, tells BioMedReports about his company and shares with readers some of his own perspectives of the events surrounding the high profile case that could impact share prices of both companies going forward.

In addition, Richman shares information about his company's own development pipeline and some of the upcoming catalysts that could also impact their market-cap.

The complete report is available at: http://biomedreports.com/2010120360907/closer-look-pharmathene-and-the-lawsuit-against-siga-technologies.html

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can also access that information at:

http://biomedreports.com/fda-calendar/fda-calendar.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1441326


Media Contacts Only:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail: Email Contact
Tel: +1 323 472 4480
Fax: +1 888 210 3556






Source: Marketwire (December 3, 2010 - 7:50 AM EST)
Servus Miteinander,

bin wieder zurück, hier gab es ja zum Glück kaum große Veränderungen.
Bin gespannt wie die Sache mit PharmAthene ausgeht und was noch im Fall SBA zu verkünden gibt.

cultom
Antwort auf Beitrag Nr.: 40.664.949 von cultom4president am 07.12.10 17:17:56Cultum: Habe auch während Deiner Abwesenheit gut auf die Siga aufgepasst.

Ich bin jetzt aus gesundheitlichen Gründen erst mal nicht mehr Online. Kannst Du dafür sorgen, daß Siga bis Weihnachten noch ein Geschenk für uns eintütet.:cool:
Kleiner Chef

Ich werde mich darum kümmern! ;)

Dir alles Gute und melde dich gesund und munter im neuen Jahr!

cultom
Siga `Guaranteed' License on Smallpox Drug, Ex-PharmAthene Chief Testifies

Siga Technologies Inc. officials “guaranteed” that PharmAthene Inc. would get manufacturing rights to a drug designed to fight smallpox outbreaks linked to terrorist attacks, PharmAthene’s former chief executive officer testified.

To spur merger talks between the two biotechnology companies, Siga’s then-Chairman Donald Drapkin vowed to grant PharmAthene a license to make the smallpox antiviral ST-246 and had terms of the agreement written out, ex-PharmAthene CEO David Wright said today at a trial over the alleged accord.

Drapkin “guaranteed it -- that we would either have a merger or a license to the product,” Wright testified in Delaware Chancery Court in Wilmington.

PharmaAthene, based in Annapolis, Maryland, sued New York- based Siga in 2006, asking a judge to affirm the purported licensing agreement for the drug, which has grabbed the attention of U.S. officials seeking ways to counter potential biological attacks by terrorists. Siga contends that the licensing talks never concluded and that the written term sheet bore the heading “non-binding.”

Siga said in October that the U.S. Health and Human Services Department selected it for a $500 million contract to produce 1.7 million doses of its smallpox antiviral. The contract may generate as much as $2.8 billion, according to court filings. Federal officials are investigating whether Siga qualifies for the contract.

‘Wouldn’t Back Out’

In a January 2006 meeting, Drapkin sought “assurance from the PharmAthene board that the company wanted to do a merger and wouldn’t back out,” Wright said. Wright said he reassured Drapkin, who at the time was also vice chairman of Ronald Perelman’s holding company, MacAndrews & Forbes Holdings Inc.

MacAndrews & Forbes had invested $10 million in Siga and was the company’s largest shareholder when it began talks with PharmaAthene over a possible merger or license for the smallpox treatment, according to court papers.

Drapkin, a former mergers-and-acquisitions lawyer with New York-based law firms Cravath, Swaine & Moore LLP and Skadden, Arps, Slate, Meagher & Flom LLP, joined MacAndrews & Forbes in 1987.

At a March 2006 meeting, Drapkin told PharmAthene executives he had secured enough Siga board votes to ensure approval of a merger, and guaranteed that the company would either grant the license or pursue a combination, Wright testified.

No Bentley

“This was also the meeting where he promised that, if we got the stock price over $5 together, he would buy me a Bentley convertible,” Wright recalled. “I never got that either.”

Andre Bouchard, a lawyer representing Siga, denied in court filings that Drapkin “orally guaranteed PharmAthene a license.” The companies “agreed only to negotiate a potential collaboration,” Bouchard wrote.

During cross-examination today, Wright acknowledged that the “non-binding” heading was never removed from the term sheet during the more than six months of negotiations between the companies.

“In hindsight, it was an error of omission,” Wright told Harold Weinberger, one of Siga’s lawyers. Wright also acknowledged that Siga officials paid off a $3 million loan that helped fund the smallpox drug’s development.

Both companies develop products to counter biological warfare agents, such as smallpox and anthrax. PharmAthene had a net loss of $32.3 million on 2009 sales of $27.6 million. Siga posted a net loss of $17.6 million on revenue of $13.8 million.

PharmAthene rose 16 cents, or 3.8 percent, to $4.39 at 2:01 p.m. in NYSE Amex trading. Siga dropped 26 cents, or 1.9 percent, to $13.74 in Nasdaq Stock Market trading.

In November, Judge Donald Parsons denied Siga’s bid to limit the scope of the trial or have part of the case dismissed.

The case is PharmAthene Inc. v. Siga Technologies Inc., CA2627, Delaware Chancery Court (Wilmington).

http://www.bloomberg.com/news/2011-01-03/pharmathene-siga-to…
Antwort auf Beitrag Nr.: 40.792.855 von Mandala64 am 03.01.11 23:11:46Dies könnte zu einer kleinen "Neverending-Story" werden.
Mal abwarten.
Antwort auf Beitrag Nr.: 40.800.359 von cultom4president am 04.01.11 23:17:51Zumindest kommt jetzt etwas Bewegung wieder rein:

PharmAthene Funded Siga Drug Trial, Official Says


PharmAthene Inc. provided funding to Siga Technologies Inc. to conduct a human safety trial of a drug designed to fight smallpox outbreaks linked to terrorist attacks, a PharmAthene official testified.

Siga was persuaded by PharmAthene to conduct the first phase of human safety trials for its smallpox antiviral ST-246 without funding from the U.S. National Institutes of Health in order to get human data on the product faster, Valerie Riddle, PharmAthene’s senior vice president and medical director, testified yesterday in Delaware Chancery Court.

“PharmAthene provided the funding to Siga,” Riddle said during the second day of a trial in PharmAthene’s lawsuit against Siga over a licensing agreement for the smallpox medicine.

PharmAthene, based in Annapolis, Maryland, sued New York- based Siga in 2006, asking a judge to affirm the purported licensing agreement for the drug, which has gotten the attention of U.S. officials seeking ways to counter potential biological terror attacks. Siga contends there is no license and the company isn’t legally bound by documents prepared for a deal.

Riddle testified that PharmAthene also helped Siga prepare for a site meeting for a contract proposal that it submitted to the NIH. In addition, PharmAthene advised Siga on applying for a drug designation that provides for tax credits and marketing incentives, she said.

“Working toward developing 246 was the goal regardless of the business arrangement,” Riddle said. “I always thought we would get 246 either under a merger agreement or under a license arrangement.”

Former PharmAthene Chief Executive Officer David Wright testified Jan. 3 that Siga officials “guaranteed” the two companies would either merge or that Siga would license the drug to PharmAthene. He also acknowledged that Siga paid off a $3 million loan that helped fund the drug’s development.

The case is PharmAthene Inc. v. Siga Technologies Inc., CA2627, Delaware Chancery Court (Wilmington).


http://www.bloomberg.com/news/2011-01-05/primary-global-stan…
Antwort auf Beitrag Nr.: 40.805.257 von cultom4president am 05.01.11 17:21:23Eine etwas ausführlichere Zusammenfassung:

http://www.milbank.com/NR/rdonlyres/E8C848E4-2D3D-4DBE-9356-…
February 01, 2011
Best-Rated Healthcare Stocks (Feb 1, 2011)

This ranking was UPDATED TODAY before 4:30 AM ET. Below are the best-rated U.S.-listed Healthcare stocks based on average rating by Wall Street analysts. Each analyst rating is assigned a number ranging from 1 to 5, with 1 being the highest rating (STRONG BUY) and 5 being the lowest rating (STRONG SELL). Then the average is calculated to represent the overall rating of a stock.

Ranking | Company (Ticker) | Average Rating Value | Average Rating
1 China Nuokang Bio-Pharmaceutical Inc. (NASDAQ:NKBP) 1.00 Strong Buy
2 EDAP TMS S.A. (ADR) (NASDAQ:EDAP) 1.00 Strong Buy
3 Compugen Ltd. (USA) (NASDAQ:CGEN) 1.00 Strong Buy

110 SIGA Technologies, Inc. (NASDAQ:SIGA) 1.50 Strong Buy

456 PharmAthene, Inc. (AMEX:PIP) 2.67 Neutral

http://www.nasd100.com/2011/02/best-rated-healthcare-stocks-…
RBC Capital continues to expect Siga Tech ( SIGA ) to obtain a lucrative contract from BARDA, and the firm thinks that the Street's fears about the company's litigation with PharmAthere (PIP) are overdone. The firm maintains a $17 target and Outperform rating on SIGA ."
http://www.theflyonthewall.com/permalinks/entry.php/SIGA;PIP…
New Smallpox Antiviral Procurement Commenced
New Smallpox Antiviral Procurement Commenced
Feb. 21, 2011 (GlobeNewswire) --
NEW YORK, Feb. 21, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that the Biomedical Advanced Research and Development Authority (BARDA), a unit of the U.S. Department of Health and Human Services, has advised that it is issuing a new Request for Proposal, number 11-100-SOL-00007, seeking to procure 1.7 million courses of a smallpox antiviral. The Request for Proposal also proposes that the contract would contain an option to procure up to 12 million additional courses. BARDA's previous Request for Proposal on this subject, number 09-35, has been cancelled. Responses to the new Request for Proposal are due February 28, 2011.

Dr. Eric A. Rose, SIGA's Chairman and Chief Executive Officer, noted, "This new Request for Proposal confirms the Government's commitment to a robust biodefense and the procurement of meaningful, new medical countermeasures against the most serious biothreats. SIGA intends to respond to this Request for Proposal, and we believe that we are well positioned to meet the Government's needs."

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/.

The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504
Vorbörslich wird die Nachricht hervorragend aufgenommen, vielleicht geht es heute wieder durch die 14USD!
Die 14USD sind schon da,hier der Grund

SIGA Technologies Inc announces new Request for Proposal for 1.7m courses of smallpox antiviral
SIGA Technologies Inc announces new Request for Proposal for 1.7m courses of smallpox antiviral
Feb. 22, 2011 (M2 Communications Ltd.) --

Pharmaceutical agents supplier SIGA Technologies Inc (Nasdaq:SIGA) said on Monday that it has received a new Request for Proposal, number 11-100 -SOL-00007, seeking to procure 1.7m courses of a smallpox antiviral.

This Request for Proposal has been committed by the Biomedical Advanced Research and Development Authority (BARDA), a unit of the US Department of Health and Human Services.

The company added the Request for Proposal also covers an option to procure up to 12m additional courses as part of the proposed deal.

In addition, the company said it plans to respond to BARDA'S new Request for Proposal on 28 February 2011.

(Comments on this story may be sent to info@m2.com)




Source: M2 Presswire (February 22, 2011 - 4:43 AM EST)

News by QuoteMedia
www.quotemedia.com
Antwort auf Beitrag Nr.: 41.085.059 von mrsun am 22.02.11 16:13:11Wie immer zählt der Schlusskurs! :)
Aber das wird schon bei SIGA.
Na da kam heute aber ordentlich Schwung rein. Ich glaube das sich die eine oder andere Problematik heute gelöst hat. Mal schauen welche NEWS kommen.
hallo,jemand zu hause,oder keiner mehr mit dabei?!
für alle anderen:

SIGA Technologies Awarded U.S. Government Contract Valued at Up to $2.8 Billion
May 13, 2011 (GlobeNewswire) --
NEW YORK, May 13, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) to deliver two million courses of its smallpox antiviral, ST-246®, to the Strategic National Stockpile. The 5-year base contract award is worth $433 million and includes options that would raise the contract's total value to approximately $2.8 billion, if these options are fully exercised. Contract options include the delivery of up to 12 million additional courses of ST-246®.

"BARDA's selection of ST-246® for the Strategic National Stockpile underscores the U.S. government's commitment to Project BioShield and the procurement of medical countermeasures to address the threat of a smallpox attack," stated Dr. Eric A. Rose, SIGA's Chairman and Chief Executive Officer. "The contract award confirms SIGA's status as a leader in the biodefense industry and highlights our abilities in drug discovery, development and commercialization. Within just five years of the first non-human primate trial for ST-246®, we are getting ready to deliver the world's first completely new small-molecule drug to address a major bioterrorism threat and one of the most lethal diseases in history. We value our new role as a provider of biodefense countermeasures to the U.S. government, which is the culmination of years of successful research and development collaborations with the U.S. government that have enabled us to take this drug to the commercial stage. We believe this keystone contract is a historic event for the biodefense industry and will be the first of many commercial successes for ST-246® here and around the world."

Under the contract, SIGA will deliver 1.7 million courses of ST-246®. Additionally, SIGA will contribute 300,000 courses manufactured using federal funds provided by HHS under prior development contracts. In addition to the option to purchase up to an additional 12 million courses, the contract will also permit SIGA to continue its work on pediatric and geriatric versions of the drug as well as use of ST-246® for smallpox prophylaxis. Dr. Rose added, "We believe that the funding to extend ST-246® to these vulnerable populations is critical to the future success of the U.S. government's smallpox biodefense efforts. There are approximately 64 million children in the United States (through age 15), none of whom is currently vaccinated against this disease."

SIGA's groundbreaking drug, ST-246®, is an oral therapeutic agent active against orthopoxviruses including smallpox. While no longer present naturally in the environment, smallpox is considered a formidable bioterrorism threat, and there is currently no FDA-approved treatment for symptomatic individuals. ST-246® works by blocking the ability of the virus to spread to other cells, preventing it from causing disease. The FDA has designated ST-246® for "fast-track" status, creating a path for expedited FDA review and eventual regulatory approval.

die letzten käufe heute nacht:

$15.9800 200 NGS 19:59:55
$16.0500 100 NGS 19:57:22
$16.0700 403 NGS 19:53:05
$16.0800 279 NGS 19:52:31
t$15.9800 401 NGS 19:51:24
t$15.9800 100 NGS 19:51:24
$15.9800 287 NYE 19:50:05
t$15.9800 100 NYE 19:50:02
$15.9900 300 NYE 19:49:58
$15.9900 800 NGS 19:49:58
t$15.9900 200 NYE 19:49:53
$16.0000 600 NGS 19:49:50
t$16.0500 500 EDGX 19:49:36
t$16.0500 100 NGS 19:49:22
t$16.0500 900 NGS 19:49:16
t$16.0000 200 NYE 19:44:32
$16.0000 800 NYE 19:44:30
$16.0000 200 NYE 19:44:30
t$16.0000 400 NYE 19:44:12
t$16.0000 400 NYE 19:44:11
$15.9900 1,000 NGS 19:44:10
$15.9900 188 NGS 19:44:10
$15.9800 100 NGS 19:43:46
$15.9800 200 NGS 19:43:20
$15.9500 300 NGS 19:43:20
$15.9800 112 NGS 19:31:27
$15.9700 488 NGS 19:31:27
$15.9800 175 NGS 19:21:29
$15.9800 200 NGS 19:20:11
$15.9800 400 NGS 19:20:09
@Mr Nun: Klar bin ich noch an Bord. Bei soviel
Tick-Tock muß man beim Big-Beng auch present sein:

SIGA Technologies: After-Hours Trading
By Michael Baron 05/13/11 - 06:59 PM EDT

The stock was last quoted at $15.88, up 12%, on volume of around 140,000, according to Nasdaq.com. Based on a regular session close at $14.19, the shares had gained 3.4% so far in 2011.
"We believe that the funding to extend ST-246 to these vulnerable populations is critical to the future success of the U.S. government's smallpox biodefense efforts," said Eric Rose, the company's chairman and CEO, in a press release. "There are approximately 64 million children in the United States (through age 15), none of whom is currently vaccinated against this disease."
SIGA said ST-246 has been designated for "fast track" status by the Food and Drug Administration, "creating a path for expedited FDA review and eventual regulatory approval."
The four analysts covering the stock were already bullish ahead of the news with two rating the shares at strong buy, and two at buy. The median 12-month price target for the stock sits at $17.

Gruß
Bin mal gespannt was mit PIP passiert,der ansatz sieht schon mal ganz gut aus,obwohl die geschichte mit dem agreement immer unglaubwürdiger beim richter ankommt.Naja,die hoffnung stirbt ja bekanntlich zuletzt.

Detailed Quote for SIGA Technologies Inc. (SIGA)
$ 14,19 RTx -0,29 (-2.00%) Volume: 555,07 k 16:00 EDT 13.05.2011

After Hours: $ 15,98 1,79 (+12.61%) Volume: 193,01 k 19:59 EDT 13.05.2011



Detailed Quote for PHARMATHENEINC (PIP)
$ 3,81 RTx -0,10 (-2.56%) Volume: 774,52 k 16:01 EDT 13.05.2011

After Hours: $ 4,20 0,39 (+10.24%) Volume: 98,1 k 19:59 EDT 13.05.2011


wie zu sehen hängt sich alles an SIGA fest und hofft auf das was da kommt oder nicht kommt. hihihi
und wieder das gleiche spiel,wann geben die jungs von Chimerix, Inc. endlich auf und akzeptieren einfach mal die fakten,daß siga das bessere produkt hat und alle anforderungen erfüllen.!!

NEW YORK, May 15, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has informed SIGA that Chimerix, Inc. has filed a post-award protest against BARDA with respect to the Government's contract with SIGA to deliver smallpox antiviral ST-246(R) to the Strategic National Stockpile. Work under the contract will be suspended until further notice pursuant to the applicable protest rules. SIGA's previous HHS contracts for advanced development of ST-246(R) for therapeutic use, intravenous formulation of the drug and post-exposure prophylaxis are unaffected by the protest, as is SIGA's work on commercial-scale validation of the oral adult formulation.



Chimerix filed its protest with the U.S. Government Accountability Office (GAO), which has the authority to decide protests concerning the procedures under which a contract is awarded. BARDA has indicated to SIGA that the Government intends to defend its decision to contract with SIGA. GAO protests are generally resolved in no more than 100 days.



Dr. Eric A. Rose, SIGA's Chairman and Chief Executive Officer, commented, "We are undaunted by what we believe will be a brief delay in starting work on this important bioterrorism defense contract and will make every effort to deliver our smallpox antiviral drug to the Strategic National Stockpile as soon as possible. SIGA is uniquely positioned to assist the Government in its efforts to protect our nation against the threat of smallpox, and we are confident that the Government's decision to award this contract to SIGA will be upheld as entirely proper."



SIGA's groundbreaking drug, ST-246(R), is an oral therapeutic agent active against orthopoxviruses including smallpox. While no longer present naturally in the environment, smallpox is considered a formidable bioterrorism threat, and there is currently no FDA-approved treatment for symptomatic individuals. ST-246(R) works by blocking the ability of the virus to spread to other cells, preventing it from causing disease. The FDA has designated ST-246(R) for "fast-track" status, creating a path for expedited FDA review and eventual regulatory approval.



Further information concerning ST-246(R) and the BARDA contract are available in the separate press releases issued by SIGA and BARDA on May 13, 2011.
Siga shares fall on reports of Congressional investigation

Tue Jun 14, 2011 10:59am EDT

(Reuters) - Shares of Siga Technologies Inc (SIGA.O) fell 8 percent Tuesday, a day after a media report said two Congressional committees were investigating the award of a multi-billion dollar government smallpox drug contract.

In a report late Monday, CNBC said the two committees were investigating whether financier Ron Perelman's political connections helped the company secure the deal.

Perelman controls about 30 percent of Siga's outstanding shares.

Last month, a unit of the United States Department of Health and Human Services (HHS) awarded Siga a contract worth up to $2.8 billion to supply its ST-246 smallpox antiviral to the U.S. Strategic National Stockpile.

"The news of a congressional investigation into the award of the smallpox contract to Siga is one more overhang that needs to be cleared, but it does not change the basic fact that (HHS) wants ST-246 and Siga is the only company that can supply it," said RBC Capital Markets analyst Jason Kantor in a note.

SIGA was not immediately available for comments.

Shares of the company were down 7 percent at $11.22 in morning trade on Tuesday on Nasdaq.

(Reporting by Anand Basu in Bangalore; Editing by Saumyadeb Chakrabarty)

New User? RegisterSign InHelpTrending: Kim Cattrall Yahoo!MailMy Yahoo!NewsFinanceSportsSearch Web Search
What improvements would you like in Yahoo! Finance Message Boards? Please send us feedback.
Message Boards Settings SIGA Technologies, Inc. - Quote Info
Search : in SIGA Technologies, Inc. boardStocks S categoryStocks (A to Z) categoryAll Yahoo! Message BoardsThe Web Advanced Search
Within fields: Subject Message Body
Matching: Topics only Topics and Messages
Sentiment: AnyStrong SellSellHoldBuyStrong Buy
Posted on: Any date
Within the range:
Start date: JanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember123456789101112131415161718192021222324252627282930311999200020012002200320042005200620072008200920102011 End date: JanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember123456789101112131415161718192021222324252627282930311999200020012002200320042005200620072008200920102011



Yahoo! Message Boards > Business & Finance > Investments > Stocks (A to Z) > Stocks S > SIGA Technologies, Inc. View all Topics | View all Messages < Newer Topic | Older Topic >
RBC Chimes In 16 minutes ago The news of a congressional investigation into the award of the smallpox contract to Siga is one more overhang that needs to be cleared, but it does not change the basic fact that (HHS) wants ST-246 and Siga is the only company that can supply it," said RBC Capital Markets analyst Jason Kantor in a note.

http://www.reuters.com/article/2011/06/14/us-siga-idUSTRE75D3U720110614?feedType=RSS&feedName=globalMarketsNews&rpc=43
Stocks To Watch This Week: TTNP, DNDN, CYTR, AMZN, SIGA, CDXC, CPST, CTSO, BDSI, SIRI, IMUC, CELH
No CommentsPosted 05 Jul 2011
Category AMZN, BDSI, CDXC, CELH, CPST, CTSO, CYTR, DNDN, IMUC, Investing, Market News, SIGA, SIRI, Trading, TTNP By VFC’s Stock House

SIGA: Encouraging news released last week didn’t do much for the share price as SIGA Technologies (NASDAQ:SIGA) ticked lower even after Chimerix withdrew its appeal to the recent awarding of a BARDA contract that has the company set to provide the US national biodefense stockpile with 1.7 million doses of its ST-246 smallpox antiviral.

According to statistics presented on Yahoo! Finance, SIGA’s short interest is roughly 20% of the float, a significant number for a company that has so much going for it right now.

The slip to below ten bucks, while discouraging to some investors, might have provided a nice entry point for those looking down the road. Now that the BARDA contract award is able to move forward without impediment, the US Government will start transferring money into the SIGA bank accounts immediately, and this could just be the beginning of a relationship that lasts a long time.

The heavy short interest may keep some downward pressure on the stock over the short term, but SIGA should have no trouble surpassing its 52-week highs over the mid to long term.

Definitely a story worth watching.

http://marketplayground.com/2011/07/05/stocks-to-watch-this-week-ttnp-dndn-cytr-amzn-siga-cdxc-cpst-ctso-bdsi-siri-imuc-celh/
Was für eine Meldung heute, bin auf das Statement zur Klage von PharmAthene gespannt. Jedenfalls ein sehr schwarzer Tag heute.
so sieht die wahrheit nun mal aus

SIGA Comments on Court Ruling in PharmAthene Litigation
NEW YORK, Sept. 22, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that the Delaware Court of Chancery has issued its post-trial opinion in the litigation commenced by PharmAthene, Inc. in 2006. The Court denied PharmAthene's contention that a draft license term sheet attached to the parties' 2006 merger agreement was a binding license and denied PharmAthene's request for specific performance of the alleged license. The Court ruled in PharmAthene's favor, however, on its claims for promissory estoppel and breach of the duty to negotiate a license agreement. The Court, after acknowledging that PharmAthene did not establish a right to any traditional form of relief on these claims, awarded to PharmAthene an "equitable payment stream" consisting of 50% of the net profits that SIGA achieves from the next ten years of sales of ST-246®, its smallpox drug, after the first $40 million of net profits goes entirely to SIGA.

Commenting on the opinion, SIGA's Chief Executive Officer Dr. Eric A. Rose commented, "We are gratified that the Court appreciated that the draft term sheet did not constitute a binding license agreement, but we respectfully disagree with the unprecedented decision to grant to PharmAthene a continuing interest in the net profits of this life-saving drug, which SIGA has worked so hard to bring to commercialization. We are continuing to study our options, but, at this point, we believe that we will appeal the unfavorable aspects of today's decision. Most importantly, while we formulate our legal strategy with regard to today's ruling, we remain committed to continuing our leadership in developing life-saving biodefense drugs and the smooth execution of the $433 million contract awarded to SIGA by BARDA earlier this year."
hallo siga
auf yahoo board wird ganz heiss über eine übenahme von pip durch siga diskutiert.beim jetzigen preis von 75 millionen marketcap noch weit entfernt,aber bei einem weiteren preisverfall bis unter 1$ von pip sieht die sache schon ganz anders aus.
verblüffend wie eine aktie in die knie geht wenn in den nächsten 5 jahren über 200 millionen an royalities winken,bei einem spieleinsatz von grade mal 3 millionen.
meinungen gern erwünscht
Allen Skeptikern zum Trotz,die ersten Gelder fliessen,auch wenn Obamah um jeden Dollar kämpft und PIP mit die Hand aufhält.
Ergo,könnte der Auftrag im Wert von 2,8 Milliarden auch noch drin sein.

http://files.shareholder.com/downloads/SIGA/1564022042x0xS922423-11-445/1010086/filing.pdf

On December 6, 2011, SIGA Technologies, Inc. (the “Company”) received a payment of approximately $36 million from the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (“BARDA”). This payment, in combination with a previously received payment of approximately $5 million, constitutes full receipt of approximately $41 million in advance payments permitted under the Company’s $435 million amended smallpox antiviral contract (HHSO100201100001C) with BARDA (the “Smallpox Antiviral BioShield Contract”).



The Project BioShield Act of 2004 (Public Law 108-276) and the Pandemic and All-Hazards Preparedness Act (Public Law 109-417) authorize advance payments under BioShield procurement contracts such as the Smallpox Antiviral BioShield Contract. The above-referenced advance payments from BARDA provide funding to, among other things, support program management, security upgrades, purchasing of raw materials and commencing commercial manufacturing until the Company is eligible to invoice the government after delivery of the first 500,000 treatment courses.




Item 9.01. Financial Statements and Exhibits.



(c) Exhibits





Exhibit No. Description


SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


SIGA TECHNOLOGIES, INC.


By: /s/ Daniel J. Luckshire

Name: Daniel J. Luckshire

Title: Chief Financial Officer

Date: December 12, 2011
Ist hier noch jemand dabei?

Habe mich hier in den letzten beiden Wochen dick eingedeckt. 2013 und 2014 wird die Ernte eingefahren.

Mit einem geschätzten KGV13 von 2 könnte SIGA nächstes Jahr durchstarten.
SIGA bestätigt das Eintreffen des nächsten Milestones. Im 4. Quartal erwartet man Mittelzuflüsse aus dem BARDA-Vertag in Höhe von 12 Mio Dollar.

http://seekingalpha.com/article/980181-siga-technologies-ceo…


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.